medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Hematopoietic mosaic chromosomal alterations and risk for infection among 767,891 individuals
without blood cancer
Seyedeh M. Zekavat BS*1-3, Shu-Hong Lin PhD*4, Alexander G. Bick MD PhD5,2, Aoxing Liu
PhD6, Kaavya Paruchuri MD2,3,7, Md Mesbah Uddin PhD2,3, Yixuan Ye BS1, Zhaolong Yu BS1,
Xiaoxi Liu PhD8, Yoichiro Kamatani PhD8, James P. Pirruccello MD2,3,7, Akhil Pampana MS2,3,
Po-Ru Loh PhD2,7, Puja Kohli MD MMSc10,11, Steven A. McCarroll PhD12,13, Benjamin Neale
PhD12,14, Eric A. Engels MD MPH4, Derek W. Brown PhD4, Jordan W. Smoller MD ScD12,15,16,
Robert Green MD MPH2,7,9, Elizabeth W. Karlson MD MS7,17, Matthew Lebo PhD18,19, Patrick
T. Ellinor MD PhD2,3,7, Scott T. Weiss MD MS7,20, Mark J. Daly6, The Biobank Japan Project,
FinnGen Consortium, Chikashi Terao MD PhD8,21,22, Hongyu Zhao PhD1,23, Benjamin L. Ebert
MD PhD2,24,25, COVID-19 Host Genetics Initiative, Andrea Ganna PhD6,14,2, Mitchell J.
Machiela ScD MPH#4, Giulio Genovese PhD#2,12,9, Pradeep Natarajan MD MMSc#2,3,7
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.

Computational Biology & Bioinformatics Program, Yale University, New Haven, CT
Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA
Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center
Institute for Molecular Medicine Finland, Helsinki, Finland.
Department of Medicine, Brigham and Women‚Äôs Hospital, Harvard Medical School, Boston, MA
Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Department of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA
Vertex Pharmaceuticals, Boston, MA
Stanley Center, Broad Institute of Harvard and MIT, Cambridge, MA
Department of Genetics, Harvard Medical School, Boston, MA
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA
Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA
Department of Psychiatry, Harvard Medical School, Boston, MA
Division of Rheumatology, Inflammation and Immunity, Brigham and Women‚Äôs Hospital, Boston, MA
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Laboratory for Molecular Medicine, Partners Healthcare, Cambridge, MA
Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA
Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan
The Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Department of Biostatistics, Yale School of Public Health, New Haven, CT
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Howard Hughes Medical Institute, Boston, MA, USA

* These authors equally contributed to this work.
# These authors equally supervised this work.
Please address correspondence to:
Pradeep Natarajan MD, MMSc
Massachusetts General Hospital
185 Cambridge Street, CPZN 3.184
Boston, MA 02114
Office: 617-726-1843
Email: pnatarajan@mgh.harvard.edu
Twitter: @pnatarajanmd

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Summary Paragraph:

2
3

Age is the dominant risk factor for infectious diseases, but the mechanisms linking the two are

4

incompletely understood1,2. Age-related mosaic chromosomal alterations (mCAs) detected from

5

blood-derived DNA genotyping, are structural somatic variants associated with aberrant

6

leukocyte cell counts, hematological malignancy, and mortality3-11. Whether mCAs represent

7

independent risk factors for infection is unknown. Here we use genome-wide genotyping of

8

blood DNA to show that mCAs predispose to diverse infectious diseases. We analyzed mCAs

9

from 767,891 individuals without hematological cancer at DNA acquisition across four

10

countries. Expanded mCA (cell fraction >10%) prevalence approached 4% by 60 years of age

11

and was associated with diverse incident infections, including sepsis, pneumonia, and

12

coronavirus disease 2019 (COVID-19) hospitalization. A genome-wide association study of

13

expanded mCAs identified 63 significant loci. Germline genetic alleles associated with expanded

14

mCAs were enriched at transcriptional regulatory sites for immune cells. Our results link mCAs

15

with impaired immunity and predisposition to infections. Furthermore, these findings may also

16

have important implications for the ongoing COVID-19 pandemic, particularly in prioritizing

17

individual preventive strategies and evaluating immunization responses.

2

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

With advancing age comes increased susceptibility to infectious diseases1,2. Immunosenescence

2

is the age-related erosion of immune function, particularly with respect to adaptive immunity12-

3

15

4

infections, with impaired immune responses increasing risk for infections16-18. Age-related

5

mosaic chromosomal alterations (mCAs) detected from blood-derived DNA, are clonal structural

6

somatic alterations (deletions, duplications, or copy neutral loss of heterozygosity) present in a

7

fraction of peripheral leukocytes that can indicate clonal hematopoiesis (CH)3-5. mCAs are

8

associated with aberrant leukocyte cell counts, and increased risks for hematological malignancy

9

and mortality3-11.

. Leukocytes, including T-cells and B-cells, are key mediators of adaptive host defenses against

10
11

While the relationship between mCAs and increased hematologic cancer risk is well established3-

12

5

13

We hypothesized that mCAs increase risk of infection since mCAs are somatic variants that

14

increase in abundance with age and are associated with alterations in leukocyte count. In this

15

study, we harnessed DNA genotyping array intensity data and long-range chromosomal phase

16

information inferred from 767,891 individuals across four countries to analyze the associations

17

between expanded mCA clones (i.e., mCAs present in at least 10% of peripheral leukocyte DNA

18

indicative of clonal expansion) and diverse infections, including severe coronavirus disease 2019

19

(COVID-19) from SARS-CoV-2 infection (Figure 1a). To elucidate genetic risk factors for the

20

development of expanded mCA clones, we performed a genome-wide association study (GWAS)

21

in the UK Biobank and subsequent in silico cell-specific, transcriptomic, and pathway analyses.

, the impact of mCAs on age-related diminishment in immune function is poorly understood.

22

3

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Results:

2
3

Population characteristics and mCA prevalence

4

A total of 767,891 unrelated, multi-ethnic individuals across the UK Biobank (UKB)

5

(N=444,199), Mass General Brigham Biobank (MGBB) (22,461), FinnGen (N=175,690), and

6

BioBank Japan (BBJ) (N=125,541) passing genotype and mCA quality control criteria

7

(Supplementary Notes 1-5) were analyzed (Supplementary Table 1). While UKB and BBJ

8

mCA calls were previously performed3,4, the MoChA pipeline

9

(https://github.com/freeseek/mocha) was implement to detect mCAs in MGBB and FinnGen

10

(Extended Data Figure 1) from genome-wide genotyping of blood DNA in the present study.

11

Among the UKB participants, mean age at DNA collection was 57 (standard deviation [SD] 8)

12

years, 204,579 (46.1%) were male, 188,875 (45.0%) were prior or current smokers, and 66,551

13

(15.0%) had a history of solid cancer. In the MGBB, mean age was 55 (SD 17) years, 10,306

14

(45.9%) were male, 9,094 (40.5%) were prior or current smokers, and 6,080 (27.1%) had a

15

history of solid cancer. In FinnGen, mean age was 53 (SD 18) years, 71,000 (40.4%) were male,

16

42.7% were prior or current smokers (when smoking status was available), and 31,855 (18.1%)

17

had a history of solid cancer. In BBJ, mean age was 65 (SD 12) years, 72,186 (57.5%) were

18

male, and 66,913 (53.3%) were prior or current smokers, and 25,987 (20.7%) had a history of

19

solid cancer.

20
21

In the UKB, among 444,199 unrelated individuals without a known history of hematologic

22

malignancy, 66,011 (14.9%) carried an mCA (15,350 autosomal) and 12,398 (3.2%) carried an

23

expanded mCA clone, defined as an mCA mutation present in at least 10% of peripheral

4

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

leukocytes (2,985 autosomal) (Supplementary Table 2). While most of carriers only carried one

2

mCA, 6% of individuals carried between 2 to 22 non-overlapping mCAs (Supplementary Note

3

6). In the MGBB, across 22,461 unrelated individuals without a history of hematologic cancer,

4

3,784 (16.8%) carried an mCA (1,025 autosomal) and 1,026 (5.2%) carried an expanded mCA

5

clone (337 autosomal). In FinnGen, across 175,690 individuals without a history of hematologic

6

cancer, 22,040 (12.5%) carried an mCA (3,164 autosomal), and 9,558 (5.9%) carried an

7

expanded mCA clone (1,620 autosomal). In BBJ, across 125,541 individuals without a history of

8

hematologic cancer, only autosomal mCAs were available, with 20,440 carriers (16.3%) and

9

1,676 (1.3%) that carried an expanded clone. (Supplementary Table 2).

10
11

Consistent with previous reports, the prevalence of mCAs increased with age and was more

12

common among men (Supplementary Note 7,8, and Supplementary Table 3). Across the

13

UKB, MGBB, FinnGen, and BBJ cohorts combined, the prevalence of expanded mCAs was

14

0.5% among individuals <40 years, 1.2% among 40-60 years, 7.8% among 60-80 years, and

15

26.5% among those greater than 80 years (Figure 1b), the majority of which is due to loss of X

16

in females and loss of Y in males (Supplementary Note 7). The prevalence of expanded

17

autosomal mCAs was 0.27% among individuals <40 years, 0.52% among 40-60 years, 1.5%

18

among 60-80 years, and 4.6% among those greater than 80 years (Figure 1c).

19
20

Association of mCAs with hematologic traits

21

We observed a striking association of mCA cell fraction with aberrant cell blood counts acquired

22

at the same visit as blood for genotyping (Figure 1d). Increased mCA cell fraction was

23

associated with overall increased white blood cell count with general consistency across the cell

5

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

differential components, with inflections at around cell fraction of 0.1 (Figure 1d). The strongest

2

association across all mCAs groupings (autosomal/chrX/chrY) with blood counts was between

3

expanded autosomal mCAs and increased lymphocyte count at enrollment (Beta 0.40 SD or 0.25

4

x109 cells/L; 95% CI 0.36 to 0.44 SD; P=4.2x10-84) (Extended Data Figure 2, Supplementary

5

Note 9).

6
7

Similarly, incident hematologic cancer risk was also strongly dependent on cell fraction

8

(Extended Data Figure 3a,b). We reproduced the associations of mCAs with hematologic

9

cancers with similar effects as previously described in the UKB4,5. We found that expanded

10

autosomal mCAs with cell fraction >10% were most strongly associated with incident

11

hematologic cancer (Extended Data Figure 3c), with the strongest association being for

12

incident chronic lymphocytic leukemia (HR 121.9; 95% CI 93.6 to 158.9; P=4.2x10-277);

13

although an association with myeloid leukemia was also present (HR 12.3; 95% CI 7.7 to 19.7;

14

P=2.3x10-25) (Supplementary Figure 11). While expanded chrX and chrY mCAs were also

15

associated with chronic lymphocytic leukemia, their effects were considerably lower (chrX: HR

16

24.1, 95% CI 5.8 to 99.9, P=1.1x10-5 and chrY: HR 2.0, 95% CI 1.0 to 4.0, P=0.038) (Extended

17

Data Figure 3c).

18
19

Associations with diverse infections

20

mCA presence across the genome was associated with diverse incident infections (defined in

21

Supplementary Data 1,2) (HR 1.06; 95% CI 1.04 to 1.09; P=8.6x10-8) (Supplementary Note

22

10), independent of age, age2, sex, smoking status, and first 10 principal components of ancestry

23

in the combined UKB, MGBB, and FinnGen meta-analysis. The dependence of this association

6

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

with mCA cell fraction is further visualized in Figure 2a,b, which shows an increase in

2

proportion of incident infection cases and incident sepsis cases with cell fraction, with greater

3

slopes observed at approximately cell fraction >10%. Accordingly, the associations across

4

diverse infections were stronger for expanded mCA clones, (HR 1.12; 95% CI 1.1 to 1.2;

5

P=6.3x10-7) (Figure 2c). Furthermore, among expanded mCA clones, the strongest association

6

was observed among expanded autosomal mCAs (HR 1.3; 95% CI 1.1 to 1.4; P=1.8x10-7)

7

(Figure 2c). Accounting for multiple hypothesis testing, expanded autosomal mCAs were

8

significantly associated with sepsis (HR 2.7; 95% CI 2.3 to 3.2; P=3.1x10-28), respiratory system

9

infections (HR 1.4; 95% CI 1.2 to 1.5; P=3.8x10-10), digestive system infections (HR 1.5; 95%

10

CI 1.3 to 1.7; P=2.2x10-9), and genitourinary system infections (HR 1.3; 95% CI 1.1 to 1.4;

11

P=3.7x10-4) (Figure 2c). The specific expanded autosomal mCAs implicated for infection were

12

diverse in nature ‚Äì across all chromosomes, of different sizes, and mixed across gain, loss, and

13

copy-number neutral loss of heterozygosity (CNN-LOH) mCAs (Extended Data Figure 4).

14

Further associations across 20 specific infectious disease subcategories are enumerated in

15

Supplementary Note 11. For sex chromosome mCAs, none of the incident infections achieved

16

statistical significance (P<0.005) in meta-analysis across the three cohorts; however, respiratory

17

infections were suggestively associated (expanded chrX: HR 1.5; 95% CI 1.01 to 1.9; P=0.0068;

18

expanded chrY: HR 1.09; 95% CI 1.0 to 1.2; P=0.005) (Supplementary Figure 12).

19
20
21

Risks for incident fatal infections were assessed in BBJ since non-fatal incident infectious

22

disease events are currently unavailable in BBJ. Among individuals without any cancer history in

23

BBJ, autosomal mCAs showed nominal associations with fatal incident infections (HR 1.12,

7

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

95% CI 1.0 to 1.2 P=0.04), with expanded autosomal mCAs being associated with incident

2

sepsis mortality (HR 2.0; 95% CI 1.0 to 4.2; P=0.05) (Supplementary Table 4, Extended Data

3

Figure 5), as well as pneumonia history (OR 1.3; 95% CI: 1.1 to 1.5; P=0.0019).

4
5

Sensitivity analysis for the association of expanded autosomal mCAs and incident sepsis found

6

that the association was consistently significant across different age groups (Supplementary

7

Note 13), and that it was additionally independent of a 25-factor smoking covariate10, body mass

8

index, type 2 diabetes mellitus, leukocyte count, lymphocyte count, and lymphocyte percentage

9

(Supplementary Table 5).

10
11

Stratified analyses indicated expanded autosomal mCAs in individuals with cancer prior to

12

infection (either any solid tumors, or hematologic malignancy after time of blood draw for

13

genotyping) conferred stronger effects for sepsis (HR 2.8; 95% CI 2.3 to 3.4; P=9.7x10-26) and

14

respiratory system infections (HR 1.6; 95% CI 1.4 to 1.8; P=6.1x10-12) compared to individuals

15

without a prior cancer history (sepsis: HR 1.3; 95% CI 0.8 to 2.0; P=0.33, Pheterogeneity=0.001;

16

respiratory system infections: HR 1.2; 95% CI 1.0 to 1.3; P=0.045, Pinteraction=0.001) (Extended

17

Data Figure 6,7; Supplementary Note 14,15). This interaction was driven by prevalent solid

18

cancer, not hematologic cancer after DNA acquisition for mCA genotyping (Supplementary

19

Table 6). Further multivariable adjustment indicated that incident sepsis and infection were

20

independent of chemotherapy, neutropenia, aplastic anemia, decreased white blood cell count,

21

bone marrow or stem cell transplant, and radiation effects prior to infection (with these

22

phenotypes defined using ICD-10 and ICD-9 phecode groupings19) (Extended Table 1).

23

8

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Association with COVID-19 hospitalization

2

Across 719 COVID-19 hospitalized cases in the UKB, 44 individuals (6%) carried an expanded

3

mCA clone at time of enrollment (in 2010), versus 3% among 337,877 controls. Adjusting for

4

age, age2, sex, prior or current smoking status, and principal components of ancestry, expanded

5

mCAs were associated with COVID-19 hospitalizations (OR 1.6; 95% CI 1.1 to 2.2; P=0.0082),

6

with higher effect estimates from expanded autosomal mCAs (OR 2.2; 95% CI 1.2 to 4.1;

7

P=0.02) (Figure 3a). Analyses in FinnGen showed evidence of independent replication. The

8

meta-analyzed associations across UKB and FinnGen of expanded autosomal mCAs on COVID-

9

19 hospitalization was OR 2.4, 95% CI 1.3 to 4.5, P=0.004 (Figure 3a,b). Similar to prior

10

phenotypes, the fraction of individuals hospitalized with COVID-19 increased with cell fraction,

11

with particularly strong slopes after cell fraction >10% (Figure 3c). In the UKB, further

12

sensitivity analysis was performed; the associations persisted with additional adjustment for

13

normalized Townsend deprivation index, normalized body mass index, type 2 diabetes mellitus,

14

hypertension, coronary artery disease, any cancer, asthma, and chronic obstructive pulmonary

15

disease (Extended Data Figure 8a). Additionally, similar associations were observed in the

16

UKB when comparing COVID-19 hospitalization to tested negative controls, COVID-19

17

positive to all from English provinces and, COVID-19 positive to tested negative controls

18

(Extended Data Figure 8b). Similar to the diverse nature of mCA clones observed in cases of

19

incident infection, specific mCA clones carried by COVID-19 hospitalized individuals were also

20

diverse in nature ‚Äì across multiple chromosomes, a wide range of sizes, and both gain, loss, and

21

CNN-LOH copy changes (Figure 3d). Similar effects associations effects of expanded mCAs

22

with COVID-19 were also observed with incident pneumonia in the UKB (Extended Data

23

Figure 8c).

9

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2

Germline genetic predisposition to expanded mCAs

3

To further elucidate causal factors for expanded mCA clones, we performed a genome-wide

4

association study (GWAS) in the UKB. We identified 63 independent genome-wide significant

5

loci (r2< 0.1 across 1MB windows of the genome) (Figure 4a, Supplementary Data 3). Across

6

the 63 germline variants, significant correlation was seen between different mCA categories

7

(Supplementary Note 16), suggesting the presence of shared germline genetic variants

8

predisposing to mCAs across the genome. Follow-up analyses using an additive polygenic risk

9

score comprised of 156 independent genome-wide significant variants associated with mosaic

10

loss-of-chromosome Y (mLOY) from males from a prior study in the UKB20, found significant

11

associations with expanded autosomal mCAs and expanded ChrX mCAs in females, further

12

highlighting the shared germline contributors towards mCAs across the genome

13

(Supplementary Note 17). TWAS combining the expanded mCA GWAS results with

14

GTEXv821 whole blood expression quantitative trait loci (eQTLs) using UTMOST22 prioritized

15

62 genes (P<3.2x10-6) promoting expanded mCA development (Figure 4b). While gene

16

enrichment analyses with the Elsevier Pathway Collection did not identify significantly

17

associated pathways after multiple testing correction, top pathways were linked to DNA damage

18

repair and lymphoid processes (Extended Data Figure 9a). The corresponding GWAS locus-

19

zoom plots for some of these immune-related genes are shown in Extended Data Figure 9b. To

20

prioritize tissues most implicated by these loci, tissue enrichment analyses using GenoSkyline-

21

Plus were performed. Significant enrichment was identified in immune-specific epigenetic and

22

transcriptomic functional regions of the genome (P=7.1x10-9) (Figure 4c). Further stratification

10

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

of the immune category identified specific enrichment for CD4+ T-cells (P=0.00098) (Figure

2

4d).

11

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Discussion:

2
3

Across four geographically distinct biobanks comprising 767,891 individuals without known

4

hematologic malignancy, clonal hematopoiesis (CH) represented by expanded mCAs is

5

increasingly prevalent with age but not readily detectable by conventional medical blood tests. In

6

addition to strongly predicting future risk of hematologic malignancy, expanded mCAs were also

7

associated with risk for diverse incident infections, particularly sepsis and respiratory infections.

8

These findings were robust across age, sex, tobacco smoking, and were strongest among those

9

who develop cancer. Consistent with these observations, expanded mCAs were also associated

10

with increased odds for COVID-19 hospitalization.

11
12

These results support several conclusions. First, mCA-driven CH is a potential risk factor for

13

infection. Recent work showed that CH with myeloid malignancy driver mutations, also referred

14

to as ‚Äòclonal hematopoiesis of indeterminate potential‚Äô (CHIP), predisposes to myeloid

15

malignancy and coronary artery disease23-27. Meanwhile, CH with larger chromosomal

16

alterations (i.e., mCAs) predisposes primarily to lymphoid malignancy but not coronary artery

17

disease3-5,8,9. Our observations suggest CH defined by the presence of mCAs is a risk factor for

18

infection. Since the relationship between mCAs and infection risk was not substantially

19

attenuated when adjusting for leukocyte or lymphocyte counts at baseline visit, the impact of

20

mCAs on infection risk likely acts through mechanisms independent of the impact of CH on cell

21

counts. For example, as mCAs alter gene dosage (e.g., via duplications and deletions) and

22

remove allelic heterogeneity (e.g., copy neutral loss-of-heterozygosity events) in leukocytes,

23

potential impacts on the differentiation, function, and survival of leukocytes are mechanisms that

12

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

could lead to altered infection risk. Our germline analyses specifically implicate lymphoid

2

tissues. In particular, many of the mCA susceptibility loci are the same as those found in chronic

3

lymphocytic leukemia, a condition in which lymphocyte differentiation and function is altered

4

promoting infection risk28-31. Therefore, molecular changes in leukocytes that promote clonal

5

expansion may occur at the expense of reduced ability to combat infection.

6
7

Second, the infectious disease risk associated with mCAs is exacerbated in the setting of cancer.

8

It is well-established that mCAs in blood-derived DNA increase risk for hematologic cancer3-5.

9

Furthermore, recent evidence suggests an association between mCAs detected in blood-derived

10

DNA and increased risk of select solid tumor7,10,32. Our analysis identified an interaction between

11

mCAs and prior cancer diagnosis that amplified sepsis and pneumonia risk. Importantly, this

12

interaction was restricted to individuals with solid cancers, not antecedent blood cancer. While

13

this observation could be partially due to synergistic immunosuppressive side effects of cancer

14

therapies33, the observed associations persisted despite adjustment for many of these treatments.

15

Alternatively, abnormal regulation of immune inflammatory pathways that release cytokines and

16

inflammatory cells may create chronic states of inflammation in individuals with mCAs34,35.

17

Surveillance for expanded mCA clones, particularly among those who develop solid cancer, may

18

help identify individuals at high risk for infection that could benefit from targeted interventions.

19
20

Third, our findings could have particular relevance for the ongoing COVID-19 pandemic. We

21

observed that mCAs are associated with elevated risk for COVID-19 hospitalization, with greater

22

than two-fold risk linked to expanded autosomal mCAs. Maladaptive immune responses,

23

particularly in leukocytes, increase risk for severe COVID-19 infections36-39. Awareness of

13

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

COVID-19 risk associated with mCAs may help with the prioritization of emerging prophylactic

2

treatments and initial vaccination programs. However, whether immune response to conventional

3

vaccination approaches is altered in the context of mCAs deserves further study.

4
5

This analysis of mCAs and infection had some limitations. First, our study only measures mCAs

6

at one time point for each participant. While our sampled mCA time point is likely correlated

7

with CH at time of infection, CH dynamically changes over time potentially leading to

8

differences in cellular fraction or additional undetected events that were acquired prior to

9

infection. Second, we cannot rule out the possibility of undiagnosed hematologic malignancy

10

among individuals with mCAs with only blood DNA. However, given the observed prevalence

11

of mCAs (4% by age 60 years) among individuals without diagnosed hematologic malignancy

12

and general scarcity of hematologic malignancy in the general population, we anticipate

13

undiagnosed hematologic malignancy at DNA acquisition to be uncommon. Third, despite the

14

robust adjustment and sensitivity analyses performed in our statistical analysis, including

15

adjustment for chemotherapy, bone marrow transplant, radiation, and other features associated

16

with poor cancer prognosis (neutropenia, aplastic anemia, decreased white blood cell count), we

17

cannot completely rule out the impact of residual confounding in our results from unknown or

18

unmeasured sources. Consistency across cohorts and infection types and biologic plausibility

19

mitigates this possibility, but functional studies testing the hypothesis that these represent causal

20

relationships merit consideration.

21
22

In conclusion, we report evidence for increased susceptibility to a spectrum of infectious diseases

23

in individuals carrying mCAs in a detectable fraction of leukocytes. The impacts of mCA on

14

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

infection risk are systemic, with increased susceptibility to infection observed for a variety of

2

organ systems, including severe COVID-19 presentations.

15

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2

Online Methods:

3

Study samples

4

A total of 767,891 individuals across four biobanks were analyzed: UK Biobank (UKB), Mass

5

General Brigham Biobank (MGBB), FinnGen, and Biobank Japan (BBJ)40-42. Across all three

6

cohorts, written informed consent was previously obtained from all participants. Individuals with

7

known hematologic cancer at time of or prior to blood draw for genotyping were removed from

8

all analyses. Additional information on each cohort is provided in Supplementary Note 1.

9
10

Mosaic chromosomal alteration detection

11

Mosaic chromosomal alteration (mCA) detection has been previously described in the UKB4,5

12

and BBJ3. mCA detection in the MGBB and FinnGen were performed with the Mosaic

13

Chromosomal Alterations (MoChA) software and pipeline (https://github.com/freeseek/mocha).

14

Briefly, genotype intensities were transformed to log2(R ratio) (LRR) and B-allele frequency

15

(BAF) values to estimate total and relative allelic intensities, respectively, as previously

16

described43. Further details regarding the mCA detection are provided in Supplementary Note

17

1-5. Across all three studies, expanded mCA refers to the presence of at least one detectable

18

mCA present in >10% of circulating leukocytes (e.g., cell fraction >10%). A 10% cell fraction

19

threshold was employed since this has been previously linked to greater clonal haematopoiesis-

20

related risk for incident mortality10 and myocardial infarction23, additionally this subset was

21

observed to most strongly associate with phenotypes in the UK Biobank including aberrant blood

22

cell counts, incident hematologic cancer, and incident infections (Figure 1d, 2a,b, Extended

23

Data Figure 3ab). Autosomes and sex chromosomes were also separately considered; only

24

autosomal mCAs were available for BBJ.

16

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2

Clinical outcomes

3

Definitions for infection outcomes are detailed in Supplementary Data 1,2. In the UKB, the

4

first reported occurrences over median 8-year follow-up in Category 2410 were used as

5

categorized by the UKB which maps primary care data, ICD-9 and ICD-10 codes from hospital

6

inpatient data, ICD-10 codes in death register records, and self-reported medical conditions

7

reported at the baseline, to ICD-10 codes. For each set of phenotypes grouped by organ system

8

or by category, the time to first incident event after baseline examination in individuals free of

9

prevalent history of each disease category was used. In the MGBB, electronic health record data

10

was used to define incident ICD-10 codes grouped in the same fashion after DNA collection date

11

over a median 3-year follow-up. In FinnGen, phenotypes were grouped together across ICD-8,

12

ICD-9, and ICD-10 codes (Supplementary Data 2), with incident infections defined after DNA

13

collection date over a median 3-year follow-up. In BBJ, analyses were performed using fatal

14

incident events attributed to diverse infection outcomes in Supplementary Data 1 since non-

15

fatal incident events were not available; additionally, analyses for pneumonia were performed

16

using history of pneumonia prior to genotyping, based on interviews and medical record

17

reviews41. Other clinical phenotypes defined in the UKB, MGBB, and FinnGen are detailed in

18

Supplementary Note 1 and Supplementary Data 6-8.

19
20

UKB coronavirus disease 2019 (COVID-19), from SARS-CoV-2 infection, phenotypes used in

21

the present analysis were downloaded on July 27, 2020. SARS-CoV-2 infection was determined

22

by polymerase chain reaction from nasopharygeal, oropharyngeal, or lower respiratory samples

23

obtained between March 16, 2020 and July 17, 2020. COVID-19 hospitalized cases were defined

17

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

as any individual with at least one positive test who also had evidence for inpatient

2

hospitalization (Field 40100). Controls included two sets: (1) participants from UKB English

3

recruitment centers who were not known to have COVID-19, which were individuals with

4

negative or no known SARS-CoV-2 testing or (2) participants with a negative SARS-CoV-2 test.

5

Individuals with COVID-19 of unknown or low severity (i.e., at least one positive SARS-CoV-2

6

test without a known hospitalization) were excluded from the primary analyses.

7

Replication was performed in FinnGen where SARS-CoV-2 infection was determined either by

8

polymerase chain reaction or by antibodies for samples obtained between March 2, 2020 and

9

July 27, 2020. Across both cohorts, individuals who died prior to March 1, 2020, and therefore

10

were not at risk for COVID-19 infection, were excluded from COVID-19 analyses.

11
12

Statistical methods for infection associations

13

Association analyses of expanded mCAs with primary incident infection across 10 main

14

infectious disease organ system categories (listed under ‚Äúorgan system‚Äù in Supplementary Data

15

1) were performed using Cox proportional hazards models, adjusting for age, age2, sex, ever

16

smoking status, and principal components 1-10 from the genotyping data. Time since DNA

17

collection was used as the underlying timescale. The proportional hazards assumption was

18

assessed by Schoenfeld residuals and was not rejected. Individuals with a history of

19

hematological cancer prior to DNA collection were excluded. P-value threshold for significance

20

among the primary organ system infection analyses was two-sided 0.05/10=0.005 to account for

21

multiple hypothesis-testing. Secondary and sensitivity analyses are detailed in the

22

Supplementary Note 1. Analyses of incident events were performed separately in each biobank

23

using the survival package in R (version 3.5, R Foundation, Vienna, Austria). Meta-analyses of

18

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

the UKB, MGBB, and FinnGen results were performed using a fixed effects model from the

2

meta package.

3
4

For UKB COVID-19 analyses, logistic regression was performed to estimate the association

5

between expanded mCAs and COVID-19 hospitalization using the aforementioned phenotype

6

definition, adjusting for sex, age, age2, smoking status, and the first ten principal components

7

from the genotyping data. As above, individuals with prevalent hematologic cancer were

8

excluded from analyses. For the COVID-19 analyses, statistical significance was assigned at

9

two-sided p-value < 0.05. Secondary multi-variable models were additionally adjusted for

10

normalized Townsend deprivation index44, inverse rank normalized body mass index at baseline,

11

type 2 diabetes mellitus, hypertension, coronary artery disease, any cancer, asthma, and chronic

12

obstructive pulmonary disease.

13

Genome-wide association study

14

GWAS was performed using Hail-0.2 software (https://hail.is/) on the Google cloud. Variants

15

were filtered to high-quality imputed variants (INFO score >0.4), with minor allele frequency

16

>0.005, and with Hardy-Weinberg Equilibrium P>1x10-10, as previously performed. A Wald-

17

logistic regression model was used for analysis, adjusting for age, age2, sex, ever smoking, PC1-

18

10, and genotyping array. Significant, independent loci were identified using P<5x10-8 and

19

clumping in Plink-2.0 using an r2 threshold of 0.1 across 1MB genomic windows using the 1000-

20

Genomes Project European reference panel. An additive mLOY polygenic risk score was

21

developed as such: ‚àë,*./ ùêµùëíùë°ùëé √ó ùëÜùëÅùëÉ*+ , where ùêµùëíùë°ùëé is the weight for each of the 156

22

independent genome-wide significant variants previously identified in UKB males20 and ùëÜùëÅùëÉ*+ is

23

the number of alleles (i.e., 0, 1, or 2) for ùëÜùëÅùëÉ* in female ùëó in the UKB.

19

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Cell-type enrichment analyses

2

We applied partitioned LD score regression using the LDSC software45 to perform enrichment

3

analysis using the expanded mCA GWAS summary statistics in combination with tissue-specific

4

epigenetic and transcriptomic functionality annotations from GenoSkyline-Plus22. In addition to

5

the baseline annotations for diverse genomic features as suggested in the LDSC user manual, we

6

specifically examined the enrichment signals on two tiers of annotations of different resolutions:

7

GenoSkyline-Plus functionality scores of 7 broad tissue clusters (immune, brain, cardiovascular,

8

muscle, gastrointestinal tract, epithelial, and others); and GenoSkyline-Plus functionality scores

9

of 11 tissue and cell types within the immune cluster (listed in Figure 8D).

10

Transcriptome-wide association and pathway enrichment analysis

11

Transcriptome-wide association was performed using the expanded mCA GWAS summary

12

statistics in combination with the UTMOST46 whole blood model updated to GTEXv8 (N=670).

13

Significant genes were identified using a Bonferroni cutoff of P<0.05/15,625 or 3.2x10-6.

14

Pathway enrichment analyses was performed using genes with TWAS P<0.001 using the

15

Elsevier Pathways through the EnrichR web server47.

16
17
18

20

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Data Availability:

2

UKB individual-level data are available for request by application

3

(https://www.ukbiobank.ac.uk). The mCA call set was previously returned to the UK Biobank

4

(Return 2062) to enable individual-level linkage to approved UK Biobank applications.

5

Individual-level MGBB data are available from

6

https://personalizedmedicine.partners.org/Biobank/Default.aspx, but restrictions apply to the

7

availability of these data, which were used under IRB approval for the current study, and so are

8

not publicly available. The BBJ genotype data is available from the Japanese Genotype-

9

phenotype Archive (JGA; http://trace.ddbj.nig.ac.jp/jga/index_e.html) under accession code

10

JGAD00000000123. Individual-level linkage of mosaic events can be provided by the BBJ

11

project upon request (https://biobankjp.org/english/index.html). FinnGen data may be accessed

12

through Finnish Biobanks‚Äô FinnBB portal (www.finbb.fi). Additionally, the full expanded mCA

13

genome wide association summary statistics have been uploaded onto the LocusZoom website

14

(https://my.locuszoom.org/gwas/525823/). The present article includes all other data generated or

15

analyzed during this study.

16
17

Code Availability:

18

A standalone software implementation (MoChA) of the algorithm used to call mCAs is available

19

at https://github.com/freeseek/mocha. A pipeline to execute the whole workflow from raw files

20

all the way to final mCA calls is available in WDL format for the Cromwell execution engine as

21

part of MoChA. Code for all other computations are available upon request from the

22

corresponding authors.

23

21

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Acknowledgements:

2
3

Thanks to Chris Whelan, Chris Llanwarne, Jason Cerrato, Kyle Vernest, and Khalid Shakir and

4

many other members of the Terra/Cromwell team for their help and advice in the development of

5

the MoChA pipeline. Thanks to Petr Danecek for implementing critical features needed in

6

BCFtools. Thanks to Stephen Chanock for critical input and comments. Thanks to Erikka

7

Loftfield for assistance with the 25-level smoking adjustment variable. Thanks to the participants

8

and staff of the UKB, MGBB, and BBJ. UKB analyses were conducted using Applications 7089

9

and 21552.

10
11

Funding:

12
13

P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General Hospital, and

14

grants from the National Heart, Lung, and Blood Institute (R01HL1427, R01HL148565, and

15

R01HL148050). P.N. and B.L.E. are supported by a grant from Fondation Leducq (TNE-

16

18CVD04). S.M.Z is supported by the NIH National Heart, Lung, and Blood Institute

17

(1F30HL149180-01) and the NIH Medical Scientist Training Program Training Grant

18

(T32GM136651). A.G.B. is supported by a Burroughs Wellcome Fund Career Award for

19

Medical Scientists. G.G is supported by NIH grant R01 HG006855, NIH grant R01 MH104964,

20

and the Stanley Center for Psychiatric Research. J.P.P is supported by a John S LaDue Memorial

21

Fellowship. K.P. is supported by NIH grant 5-T32HL007208-43. P.T.E. is supported by

22

supported grants from the National Institutes of Health (1RO1HL092577, R01HL128914,

23

K24HL105780), the American Heart Association (18SFRN34110082), and by the Foundation

22

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Leducq (14CVD01). P.-R.L. is supported by NIH grant DP2 ES030554 and a Burroughs

2

Wellcome Fund Career Award at the Scientific Interfaces. This work was supported by the

3

Intramural Research Program of the National Cancer Institute, National Institutes of Health,

4

extramural grants from the National Heart, Lung, and Blood Institute, and Fondation Leducq.

5

The opinions expressed by the authors are their own and this material should not be interpreted

6

as representing the official viewpoint of the U.S. Department of Health and Human Services, the

7

National Institutes of Health, or the National Cancer Institute.

8

Competing Interests:

9

P.N. reported grants from Amgen during the conduct of the study and grants from Boston

10

Scientific; grants and personal fees from Apple; personal fees from Novartis and Blackstone Life

11

Sciences; and other support from Vertex outside the submitted work. P.T.E. has received grant

12

support from Bayer AG and has served on advisory boards or consulted for Bayer AG, Quest

13

Diagnostics, MyoKardia and Novartis, outside of the present work. S.M.Z., S-H.L., M.J.M.,

14

G.G., and P.N. have filed a patent application (serial no. 63/079,74) on the prediction of infection

15

from mCAs. G.G. and S.A.M. have filed a patent application (PCT/WO2019/079493) for the

16

MoChA mCA detection method employed in the present study. No other disclosures were

17

reported.

18
19
20

23

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

a.

b.

All Expanded mCAs
(Cell fraction > 10%)
0.5

FinnGen
(N=175,690)

MGBB
(N=22,461)

BBJ
(N=125,541)

0.4

Proportion

UKB
(N=444,199)

MoChA

Terao et al.
Nature 2020

Po-Ru Loh et al.
Nature 2020

Genome-wide mCA Detection
MoChA

0.3

Male
Female

0.2
0.1
0.0

<4
0
[4
0,
45
[4 )
5,
50
[5 )
0,
55
[5 )
5,
60
[6 )
0,
65
[6 )
5,
70
[7 )
0,
75
[7 )
5,
80
[8 )
0,
85
)
>8
5

Blood Counts,
Incident
Hematologic Cancer

Age (years)

Expanded Autosomal mCAs
(Cell fraction > 10%)

c.
Exposure:
Expanded mCAs
0.075

Whole Blood
TWAS

Male
Female

0.025

UTMOST-GTEXv8

5

)

>8

)

85
0,

[8

)

80
5,

[7

)

75
0,

[7

)

70
5,

[6

)

65
0,

[6

)

60
5,

[5

)

55
0,

[5

)

50

45

0.060
0.056

Neutrophil

0.064

0.185
0.175
0.165

4.8
4.4
4.0

0

0.
5
1. 0
00

0.
1

1
0.
0

10

0.
5
1. 0
00

Cell fraction

0.

0.

01

0.
5
1. 0
00

0.

01

Cell fraction

10

0.155

0.

10

01
0.

10

0.
5
1. 0
00

0.

01

Cell fraction

Cell fraction

0.195

Eosinophil

Reticulocyte

0.036
0.032

0.

0.
5
1. 0
00

0.
10

0.
01

01

1.6
1.4

Cell fraction

Cell fraction

1.8

0.040

0.
5
1. 0
00

250

2.0

0.

260

0.044

2.2

Basophil

Lymphocyte

270

240

0.

10

0.
5
1. 0
00

0.

0.

01

6.5

Platelet

7.0

10

7.5

280

4.6
4.5
4.4
4.3
4.2
4.1

0.
5
1. 0
00

RBC

8.0

WBC

Age (years)

All mCAs

0.

c.

[4

GWAS for expanded mCAs

0,

<4

0

0.000

5,

GenoSkyline-Plus

0.050

[4

Cell-Specific Functional
Enrichment

Proportion

Incident
Infection
Mortality

Incident Infectious Diseases

Cell fraction

Cell fraction

Autosomal mCAs

Cell fraction

Cell fraction

1
2
3

24

4.3
4.2

10

0.
5
1. 0
00

10
0.

01

0.170

4.4

01

Neutrophil

0.175

4.5

0.
5
1. 0
00

Cell fraction

0.180

0.

Eosinophil
0.
5
1. 0
00

10

0.
5
1. 0
00

0.
10

Cell fraction

4.6

0.185

0.

Cell fraction

0.
01

0.03

1.2

0.060

0.

0.04

0.062

01

0.05

0.190
0.064

0.

Reticulocyte

Basophil

0.06

0.

Cell fraction

1.5

0.
5
1. 0
00

0.
5
1. 0
00

10
0.

01

0.
5
1. 0
00

10
0.

01

Cell fraction

1.8

10

240
235

0.

10

0.
5
1. 0
00

0.

01

4.50

245

0.07
2.1

0.

4.51

7.0

250

01

4.52

255

0.

4.53

0.

RBC

7.5

0.

WBC

8.0

Platelet

4.54

8.5

Lymphocyte

260

9.0

Cell fraction

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Figure 1: Study schematic. a. Genome-wide mCAs were detected across the UKB4, MGBB (via
the MoChA pipeline), FinnGen (via the MoChA pipeline), and BBJ3. Association of expanded
mCAs (cell fraction >10%) with incident infectious diseases in UKB, MGBB, and FinnGen and
with incident infectious disease mortality in BBJ was performed. A GWAS for expanded mCAs
was then performed in the UKB to discover causal factors for expanded mCAs. Using the
GWAS results, cell-specific functional enrichment analyses were performed using GenoSkylinePlus, which combines epigenetic and transcriptomic annotations with GWAS summary statistics
to estimate the relative contribution of cell-specific functional markers to the GWAS results.
Additionally, to prioritize putative causal genes and pathways promoting the development of
expanded mCAs, whole blood TWAS was performed using UTMOST via GTEx v8. Association
of b. all expanded mCAs with cell fraction >10%, and c. all expanded autosomal mCAs, with
age using 5-year age bins stratified by sex among individuals in the UKB, MGBB, FinnGen, and
BBJ combined. Plots by cohort and across other mCA groupings are available in
Supplementary Note 7, 8. d. Associations of mCA cell fraction with blood counts (in units of
10^9 cells/L) in the UKB among individuals without prevalent hematologic cancer at time of
blood draw for genotyping and cell count measurement. The dotted horizontal lines reflect the
mean blood count for individuals without an mCA. The dotted vertical lines at cell fraction of
0.10 represents the cutoff for the expanded mCA definition. Individuals with known hematologic
cancer at time of or prior to blood draw for genotyping were excluded.
BBJ = BioBank Japan, GTEx v8 = Genotype-Tissue Expression project version 8,
GWAS=genome-wide association study, MGBB = Mass General Brigham Biobank, mCA =
mosaic chromosomal alterations, MoChA = Mosaic Chromosomal Alterations software
(https://github.com/freeseek/mocha), TWAS = transcriptome-wide association study, UKB = UK
Biobank, UTMOST = Unified Test for MOlecular SignaTures.

25

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

a.

b. 4.0 International
It is made available under a CC-BY-NC-ND
license
.
Autosomal
mCAs

All mCAs

0.25

0.20

0.075

0.050

0.025

0.35

Fraction developing
incident sepsis

0.30

Fraction developing
any incident infection

Fraction developing
incident sepsis

Fraction developing
any incident infection

0.35

0.30

0.25

0.20

0.10

0.05

0.00

1
2
3 c.

0.01

0.10

0.25 0.50 1.00

0.10

0.25 0.50 1.00

0.01

Cell fraction

Effect of Any Expanded mCA
on Incident Disease

0.10

0.01

0.25 0.50 1.00

Effect
of Expanded
Autosomal
mCA
Effect
of Any Expanded
mCA
onControls
Incident Disease
Disease
P mCA (N)
Cases
Cases (N) on
(N)
Cases with HR
mCA (N)
95% CI
Controls with
Cases (N)
(N)
Incident

Cases
Cases with
with mCA
mCA(N)
(N)

57,453
57,453
7,073
7,073
3,332
3,178

226,660
226,660
10,009
10,009
28,853
27,762

2,040
497
357
112
186
32

12,049
2.9e‚àí08
5.7e‚àí26
953
0.007
7.8e‚àí05
2,652
0.51
0.91
1e‚àí08
3.1e‚àí28

5,237
5,237
611
611
403
378

437,757
437,757
21,684
21,684
60,747
58,548

307
111
60
24
30
5

[1.13;
[1.23; 1.27]
1.5]
[1.08;
[1.09; 1.44]
1.7]
[1.03;
[0.84; 1.48]
1.9]
[1.15;
1.27]
[1.24; 1.5]

8,553
1.7e‚àí09
3e‚àí08
725
0.0024
0.0067
2,131
0.021
0.26
1.2e‚àí12
3.8e‚àí10

39,158
39,158
4,411
4,411
2,019
1,896

320,202
320,202
16,249
16,249
47,237
45,463

1,480
366
222
78
145
22

7241.19
1.52
801.27
1.68
400.74
0.82
1.16
1.51

[1.09;
[1.31; 1.29]
1.8]
[1.00;
[1.18; 1.62]
2.4]
[0.53;
[0.39; 1.04]
1.7]
[1.08;
[1.32; 1.26]
1.7]

11,036
6.4e‚àí05
3.9e‚àí08
913
0.051
0.0042
2,562
0.081
0.61
9.9e‚àí05
2.2e‚àí09

19,681
19,681
1,470
1,470
1,009
976

403,978
403,978
20,256
20,256
54,479
52,348

724
205
80
32
40
7

374,865
16,859
54,868

8681.14
1.27
1741.24
1.19
691.16
1.23
1.16
1.25

[1.05; 1.23]
[1.10; 1.5]
[1.06; 1.46]
[0.91; 1.5]
[0.90; 1.51]
[0.71; 2.1]
[1.08; 1.24]
[1.11; 1.4]

10,572
0.0011
0.0011
743
0.0085
0.2
2,636
0.25
0.45
2.3e‚àí05
0.00037

24,951
24,951
3,617
3,617
1,171
1,115

374,865
374,865
16,859
16,859
54,868
52,655

868
232
174
58
69
13

793
280
62

442,684
22,031
51,538

441.03
1.74
220.97
2.19
3 1.23
1.97
1.02

[0.72; 1.46]
[0.93; 3.3]
[0.60; 1.55]
[1.21; 4.0]
[0.36; 4.20]
[1.28; 3.0]
[0.77; 1.34]

12,329
0.87
0.083
990
0.89
0.0097
1,648
0.74
0.0021
0.9

793
793
280
280
62

442,684
442,684
22,031
22,031
51,538

44
10
22
12
3

31,219
3,588
722

348,832
17,319
60,107

1.06
9780.99
1.28
1831.10
1.09
330.89
1.11
1.00

[0.92; 1.06]
1.2]
[0.92;
[1.00; 1.29]
1.6]
[0.94;
[0.48; 1.29]
2.4]
[0.62;
[0.98; 1.07]
1.2]
[0.94;

0.44
9,691
0.79
0.052
754
0.23
0.84
2,759
0.54
0.1
0.89

31,219
31,219
3,588
3,588
695
722

348,832
348,832
17,319
17,319
57,808
60,107

239
978
64
183
6
33

1,307
360
146

441,037
21,920
63,596

1.30
611.14
1.57
160.79
0.74
101.06
1.37
1.04

[0.69; 1.55]
2.4]
[0.84;
[0.80; 1.34]
3.1]
[0.47;
[0.10; 2.10]
5.4]
[0.53;
[0.88; 1.34]
2.1]
[0.81;

0.42
12,272
0.4
0.19
1,005
0.38
0.77
2,946
0.87
0.16
0.74

1,307
1,307
360
360
137
146

441,037
441,037
21,920
21,920
61,145
63,596

16
61
9
16
1
10

NervousSystem
SystemInfection
Infection
Nervous
UK
Biobank
1.07
[0.68; 1.68]
0.77
UK
Biobank
MGB
Biobank
1.24
[0.59; 2.61]
0.58
MGB
Biobank
FinnGen
1.79
[0.60; 5.32]
0.29
FinnGen
Overall
1.17
[0.82; 1.69]
0.39
Overall

675
168
64

440,150
22,210
64,625

1.44
251.07
1.36
8 1.24
2.37
4 1.79
1.49
1.17

[0.64; 1.68]
3.2]
[0.68;
[0.43; 2.61]
4.3]
[0.59;
[0.32; 17.4]
[0.60;
5.32]
[0.80; 1.69]
2.8]
[0.82;

0.37
12,283
0.77
0.6
1,013
0.58
0.4
3,010
0.29
0.21
0.39

675
675
168
168
61
64

440,150
440,150
22,210
22,210
62,119
64,625

6
25
38
14

Eye,Ear,
Ear,or
orMastoid
MastoidInfection
Infection
Eye,
UK
Biobank
1.10
[0.98; 1.24]
0.091
UK
Biobank
MGB
Biobank
1.19
[0.88; 1.62]
0.26
MGB
Biobank
FinnGen
1.05
[0.64; 1.73]
0.84
FinnGen
Overall
1.11
[1.00; 1.23]
0.049
Overall

13,009
1,008
416

402,465
21,134
60,607

1.06
3681.10
1.39
471.19
1.66
181.05
1.13
1.11

[0.85; 1.24]
1.3]
[0.98;
[0.86; 1.62]
2.2]
[0.88;
[0.68; 1.73]
4.0]
[0.64;
[0.93; 1.23]
1.4]
[1.00;

0.63
11,225
0.091
0.18
964
0.26
0.26
2,864
0.84
0.21
0.049

13,009
13,009
1,008
1,008
403
416

402,465
402,465
21,134
21,134
58,225
60,607

92
368
18
47
5
18

95% CI

P

8.8e‚àí05
0.00089
0.37
6.3e‚àí07

57,453
7,073
3,332

226,660
10,009
28,853

2,040
1.10
1.24
3571.21
1.29
1861.08
1.22
1.12
1.25

[1.05;
[1.13; 1.16]
1.4]
[1.08;
[1.06; 1.36]
1.6]
[0.92;
[0.86; 1.26]
1.7]
[1.07;
[1.15; 1.17]
1.4]

5,940
8.8e‚àí05
1.1e‚àí05
0.00089
404
0.0091
1,294
0.37
0.26
6.3e‚àí07
1.8e‚àí07

Sepsis
UK Biobank
MGB Biobank
FinnGen
Overall

Sepsis
Sepsis
1.44
[1.26; 1.63]
UK
Biobank
UK
Biobank
1.50
[1.12; 2.01]
MGB
Biobank
MGB
Biobank
0.87
[0.59; 1.30]
FinnGen
FinnGen
1.39
[1.24; 1.55]
Overall
Overall

2.9e‚àí08
0.007
0.51
1e‚àí08

5,237
611
403

437,757
21,684
60,747

3071.44
2.90
601.50
2.33
300.87
1.05
1.39
2.68

[1.26;
[2.38; 1.63]
3.5]
[1.12;
[1.53; 2.01]
3.5]
[0.59;
[0.43; 1.30]
2.6]
[1.24;
[2.25; 1.55]
3.2]

Respiratory System Infection
UK Biobank
MGB Biobank
FinnGen
Overall

Respiratory
RespiratorySystem
SystemInfection
Infection
1.20
[1.13; 1.27]
1.7e‚àí09
UK
Biobank
UK
Biobank
1.25
[1.08; 1.44]
0.0024
MGB
Biobank
MGB
Biobank
1.24
[1.03; 1.48]
0.021
FinnGen
FinnGen
1.21
[1.15; 1.27]
1.2e‚àí12
Overall
Overall

39,158
4,411
2,019

320,202
16,249
47,237

1,480
1.20
1.37
2221.25
1.37
1451.24
1.28
1.21
1.36

Digestive System Infection
UK Biobank
MGB Biobank
FinnGen
Overall

Digestive
DigestiveSystem
SystemInfection
Infection
1.19
[1.09; 1.29]
6.4e‚àí05
UK
Biobank
UK
Biobank
1.27
[1.00; 1.62]
0.051
MGB
Biobank
MGB
Biobank
0.74
[0.53;
1.04]
0.081
FinnGen
FinnGen
1.16
[1.08; 1.26]
9.9e‚àí05
Overall
Overall

19,681
1,470
1,009

403,978
20,256
54,479

Genitourinary System Infection
UK Biobank
MGB Biobank
FinnGen
Overall

Genitourinary System Infection
Genitourinary System Infection
[1.05; 1.23]
0.0011
UK1.14
Biobank
UK Biobank
1.24
[1.06; 1.46]
0.0085
MGB
Biobank
MGB Biobank
1.16
[0.90; 1.51]
0.25
FinnGen
FinnGen
1.16
[1.08; 1.24]
2.3e‚àí05
Overall
Overall

24,951
3,617
1,171

Cardiac Infection
UK Biobank
MGB Biobank
FinnGen
Overall

Cardiac Infection
Cardiac Infection
[0.72; 1.46]
UK1.03
Biobank
UK Biobank
0.97
[0.60; 1.55]
MGB
Biobank
MGB Biobank
1.23
[0.36; 4.20]
FinnGen
Overall
1.02
[0.77; 1.34]
Overall

0.87
0.89
0.74
0.9

Dermatologic Infection
UK Biobank
MGB Biobank
FinnGen
Overall

DermatologicInfection
Infection
Dermatologic
UK
Biobank
0.99
[0.92; 1.06]
UK
Biobank
MGB
Biobank
1.10
[0.94; 1.29]
MGB
Biobank
FinnGen
0.89
[0.62; 1.29]
FinnGen
Overall
1.00
[0.94; 1.07]
Overall

0.79
0.23
0.54
0.89

Musculoskeletal System Infection
UK Biobank
MGB Biobank
FinnGen
Overall

MusculoskeletalSystem
System Infection
Infection
Musculoskeletal
UK
Biobank
1.14
[0.84; 1.55]
0.4
UK
Biobank
MGB
Biobank
0.79
[0.47; 1.34]
0.38
MGB
Biobank
FinnGen
1.06
[0.53; 2.10]
0.87
FinnGen
Overall
1.04
[0.81; 1.34]
0.74
Overall

Nervous System Infection
UK Biobank
MGB Biobank
FinnGen
Overall
Eye, Ear, or Mastoid Infection
UK Biobank
MGB Biobank
FinnGen
Overall

1.5
HR

2

0.25 0.50 1.00

Controls
Controls (N)
(N)

HR

Any
AnyInfection
Infection
1.10
[1.05; 1.16]
UK
Biobank
UK
Biobank
1.21
[1.08; 1.36]
MGB
Biobank
MGB
Biobank
1.08
[0.92; 1.26]
FinnGen
FinnGen
1.12
[1.07; 1.17]
Overall
Overall

1 1.1

0.10

Cell fraction

Cell fraction

Any Infection
UK Biobank
MGB Biobank
FinnGen
Overall

0.8

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

0.01

Cell fraction

0.8
0.8

1 1 1.1

2 1.5
HR
HR

2
4

4

Figure 2: Associations of expanded mCAs with incident infections. Visualizing the dependence
with cell fraction among a. all mCAs, and b. autosomal mCAs, of any incident infection and
incident sepsis in the UKB among individuals without prevalent hematologic cancer at time of
blood draw for genotyping across. The dotted vertical lines at cell fraction of 0.10 represents the
cutoff for the expanded mCA definition. c. Association of all expanded mCAs, and separately,
expanded autosomal mCAs with incident infections across individuals in the UKB, MGBB, and
FinnGen. Analyses are adjusted for age, age2, sex, smoking status, and principal components 110 of ancestry. Individuals with prevalent hematologic cancer were excluded from analysis.
Association analyses for other groupings of mCAs (including across all mCAs regardless of cell
fraction, as well as chrX and chrY mCAs are provided in Supplementary Notes 10, 12). BBJ =
BioBank Japan, MGBB = Mass General Brigham Biobank, mCA = mosaic chromosomal
alterations, UKB = UK Biobank.

26

Contr
Contr

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

a.

It is made available under a CC-BY-NC-ND 4.0 International license .
Effect
Expanded
mCAs
Effect
ofofExpanded
mCAs
OR
95% CI
P
Cases (N)
COVID‚àí19
phenotypes
Onon
COVID-19
hospitalization

1
2
3
4
5
6
7
8
9
10
11

1.59
2.75
1.63

[1.13; 2.2]
[0.50; 15.2]
[1.16; 2.3]

0.0082
0.25
0.0048

719
14

337,877
66,584

44
2

Autosomal
UK Biobank
FinnGen
Overall

2.17
8.80
2.44

[1.16; 4.1]
[1.07; 72.3]
[1.33; 4.5]

0.016
0.043
0.0038

686
13

329,961
63,934

11
1

ChrY
UK Biobank
FinnGen
Overall

1.30
2.14
1.32

[0.87; 2.0]
[0.19; 23.5]
[0.89; 2.0]

0.2
0.54
0.17

385
7

143,825
28,874

33
1

ChrX
UK Biobank
Overall

2.86
2.86

[0.40; 20.5]
[0.40; 20.5]

0.3
0.3

324

191,661

1

0

Expanded mCA

2
OR

1

4

6

Expanded Autosomal mCA

0

1

d.

0.0075

0.0050

0.0025

0.02

0.01

0.00

50

60

70

40

Age

c.

Fraction with
COVID‚àí19 hospitalization

Fraction with
COVID‚àí19 hospitalization

60

70

Age
0.020

Expanded mCA
0.0075

0.0050

0.0025

0.0000

Expanded Autosomal mCA

0.015

0.010

0.005

0.000
0.01

0.10

0.25 0.50 1.00

Cell Fraction

12
13
14
15
16
17
18
19
20
21
22
23
24
25

50

0.01

0.10

0.25 0.50 1.00

Cell Fraction

Chromosome

Fraction with
COVID‚àí19 hospitalization

Fraction with
COVID‚àí19 hospitalization

0.0100

40

Cases with mCA (N)

All
UK Biobank
FinnGen
Overall

0.8 1

b.

Controls (N)

22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2

Cell Fraction
0.1
0.2
0.3
0.4

Copy Change
Gain
Loss
CNN‚àíLOH

1

10
mCA Size (MB)

100

Figure 3: Association of expanded mCAs with COVID-19 Hospitalization. a. Associaiton of
expanded mCAs with COVID-19 Hospitalization across the UKB and FinnGen. Individuals with
known hematologic cancer at time of or prior to blood draw for genotyping were excluded.
Analyses are adjusted for age, age2, sex, ever smoking status, and principal components of
ancestry. b. Fraction of COVID-19 hospitalizations plotted by age, stratified by Expanded mCA
(left) and expanded autosomal mCA (right) c. Fraction of COVID-19 hospitalizations plotted by
cell fraction among expanded mCAs (left) and expanded autosomal mCAs (right).
d.Visualization of the diverse range of expanded autosomal mCAs detected across the genome
among individuals hospitalized with COVID-19 in the UK Biobank. Each point represents one
mCA carried by a case, with the x-axis as the chromosome, y-axis as the mCA size in megabases of DNA (MB). Additional sensitivity analyses in the UKB are provided in Extended Data
Figure 8. MGBB = Mass General Brigham Biobank, UKB = UK Biobank, MB=megabase,
CNN-LOH = copy number neutral loss of heterozygosity

27

Contro

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

a.

b.

Expanded mCA

Whole Blood TWAS (N=670)

25

‚óè

ZBTB24

Observed - log10 (p)

20

LACE1
‚óè

ATM

SMPD2
‚óè

AK9

ACAT1

15

‚óè‚óè

SENP7

MICAL1

‚óè
‚óè‚óè
‚óè

CCM2L
MAD1L1

CCDC162P

C11orf65

‚óè
‚óè

10

‚óè
‚óè

‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
NFKB1
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
WRAP53
IL12RB1
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè
‚óè

MDC1

FLT3

5

0

0

1

d.

c.

‚óè

CD164

MRM2

2
3
Expected - log10 (p)

4

5

Mononuclear cells from peripheral blood

Immune

T cells CD3+

Brain

T cells CD4+

Tissue
Immune

CV

Brain

T cells CD8+
Monocytes CD14+

CV

Muscle

Tissue

Hematopoietic
stem cells G‚àíCSF‚àímobilized CD34+
Muscle
GI

GI

Epithelium
Other

Epithelium

Immune

B cells CD19+
Natural killer cells CD56+
GM12878 lymphoblastoid cells
Thymus

Other
Spleen

6

4

2

0

10.0

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

7.5

5.0

2.5

0.0

‚àílog(Enrichment P)

‚àílog(Enrichment P)

Figure 4: Inherited risk factors for expanded mCAs: GWAS, TWAS, and Cell Type Enrichment.
a. GWAS for expanded mCA identified 63 independent loci. b. Quantile-quantile plot of the
whole blood TWAS of the expanded mCA GWAS using 670 samples from GTExv8 shows
enrichment across 62 genes. The horizontal dotted line reflects the Bonferroni-adjusted p-value
for significance. Genes with TWAS P<5x10-8 or those important in the pathway-enrichment
analyses from Extended Data Figure 9 are labeled. c. cell-type enrichment results from the
Expanded mCA GWAS across immune, brain, cardiovascular (CV), muscle, gastrointestinal
(GI), epithelium, and other tissues as annotated using GenoSkyline-Plus annotations. D.
Zooming in to show the stratified enrichment by specific categories of immune cells and tissues.
Across panels C. and D., the vertical dotted lines indicate (1) P=0.05 for suggestive enrichment,
and (2) the Bonferroni-adjusted P-value for significant enrichment. GWAS = genome wide
association study, TWAS = transcriptome-wide association study, CV = cardiovascular, GI =
Gastrointestinal

28

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

a) MGBB

b) FinnGen
Loss

CN‚àíLOH

Gain

Loss

Undetermined

CN‚àíLOH

Gain

Undetermined

10
18

18

10

5

5
19

19

14
6

6

14

1
11

1
11

7

20
2

7
15

20

21

2

15

8

21

12

12

8
16

22

3
16

3

22
4

9
13

17

9
13

4

1
2
3
4

17

Extended Data Figure 1: mCA calls by chromosome in the MGBB and FinnGen, CN-LOH =
copy neutral loss of heterozygosity

29

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
Effect of mCAs
on blood counts (SD)

95% CI

P

Participants (N)

Participants with mCA (N)

All
White blood cell leukocyte count
Neutrophill count
Monocyte count
Red blood cell erythrocyte count
Lymphocyte count
Platelet count
Basophill count
Eosinophill count
Reticulocyte count

0.32
0.26
0.25
‚àí0.19
0.13
0.11
0.11
0.06
‚àí0.02

[ 0.31; 0.34]
[ 0.24; 0.28]
[ 0.23; 0.27]
[‚àí0.21; ‚àí0.18]
[ 0.11; 0.15]
[ 0.10; 0.13]
[ 0.08; 0.13]
[ 0.04; 0.08]
[‚àí0.04; 0.00]

2.6e‚àí227
3.9e‚àí151
8e‚àí145
2.5e‚àí113
1.3e‚àí39
6.2e‚àí31
3e‚àí24
1.6e‚àí08
0.047

430,370
429,489
427,354
430,123
429,366
429,941
428,816
406,400
422,655

11,915
11,953
11,899
11,967
11,751
11,956
11,927
11,737
11,780

Autosomal
Lymphocyte count
White blood cell leukocyte count
Basophill count
Monocyte count
Red blood cell erythrocyte count
Reticulocyte count
Neutrophill count
Platelet count

0.40
0.37
0.14
0.12
‚àí0.06
0.07
0.07
‚àí0.05

[ 0.36; 0.44]
[ 0.33; 0.41]
[ 0.09; 0.18]
[ 0.08; 0.16]
[‚àí0.10; ‚àí0.03]
[ 0.03; 0.11]
[ 0.03; 0.11]
[‚àí0.09; ‚àí0.02]

4.2e‚àí84
5.5e‚àí75
4.3e‚àí11
7.3e‚àí10
0.00012
0.00032
0.00052
0.0055

429,366
430,370
428,816
427,354
430,123
422,655
429,489
429,941

2,657
2,797
2,850
2,821
2,858
2,834
2,865
2,841

ChrY
White blood cell leukocyte count
Neutrophill count
Monocyte count
Platelet count
Red blood cell erythrocyte count
Lymphocyte count
Basophill count
Eosinophill count

0.29
0.28
0.25
0.22
‚àí0.15
0.11
0.08
0.05

[ 0.27; 0.32]
[ 0.26; 0.30]
[ 0.23; 0.28]
[ 0.19; 0.24]
[‚àí0.18; ‚àí0.13]
[ 0.09; 0.13]
[ 0.06; 0.11]
[ 0.03; 0.07]

4.7e‚àí138
2.3e‚àí124
3.2e‚àí101
8.8e‚àí74
1.1e‚àí39
4.3e‚àí21
1.1e‚àí11
1.6e‚àí05

198,676
198,290
197,945
198,487
198,545
198,198
197,901
197,711

8,875
8,848
8,839
8,873
8,865
8,844
8,837
8,828

ChrX
White blood cell leukocyte count
Lymphocyte count
Monocyte count
Neutrophill count
Platelet count

0.24
0.18
0.18
0.18
0.16

[ 0.12;
[ 0.07;
[ 0.06;
[ 0.06;
[ 0.04;

7.6e‚àí05
0.0024
0.0036
0.0036
0.0083

231,694
231,168
229,409
231,199
231,454

386
381
383
385
386

‚àí0.2 ‚àí0.1 0

3
4
5
6
7
8

Beta (SD)

0.1 0.25
Beta (SD)

0.36]
0.30]
0.30]
0.30]
0.28]

0.5

Extended Data Figure 2: Association of blood counts with expanded mCAs. Associations are
adjusted for age, age2, sex, smoking status, and principal components of ancestry. mCA = mosaic
chromosomal alterations.

30

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Autosomal mCAs
All
mCAs
0.6
b.
It is made available under a CC-BY-NC-ND 4.0 International license .

0.6

Fraction developing
incident hematologic cancer

a.

Fraction developing
incident hematologic cancer

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

0.4

0.2

0.0

0.01

0.10

0.4

0.2

0.0

0.25 0.50 1.00

0.01

0.10

Cell fraction
Effect of expanded mCAs
on Incident Cancer

c.

HR

95% CI

All
Hematologic Cancer
Lymphoid Leukemia
CLL
Any Cancer
Malignant Cancer
MPN
Lung Cancer
Myeloid Leukemia
Epithelial Cancer
Benign Cancer
Prostate Cancer
Colorectal Cancer
Skin Cancer
Breast Cancer
Nervous System Cancer
Bladder Cancer
Carcinoma in situ Cancer
ConnectiveTissue Cancer

4.09
28.94
36.44
1.34
1.33
4.30
1.91
3.88
1.15
2.60
1.18
1.20
1.09
0.85
1.13
1.06
1.07
0.99

[ 3.65;
[21.77;
[26.75;
[ 1.28;
[ 1.26;
[ 3.31;
[ 1.63;
[ 2.56;
[ 1.09;
[ 1.46;
[ 1.05;
[ 0.99;
[ 0.98;
[ 0.60;
[ 0.75;
[ 0.86;
[ 0.82;
[ 0.72;

Autosomal
Hematologic Cancer
Lymphoid Leukemia
CLL
MPN
Any Cancer
Malignant Cancer
Myeloid Leukemia
Skin Cancer
Lung Cancer
Benign Cancer
Colorectal Cancer
Carcinoma in situ Cancer
ConnectiveTissue Cancer
Epithelial Cancer
Breast Cancer
Nervous System Cancer
Bladder Cancer
Prostate Cancer

16.87
99.35
121.92
17.21
1.86
1.97
12.30
1.51
1.56
1.94
1.24
1.24
1.28
1.03
0.92
0.83
0.95
1.02

[15.03;
[77.86;
[93.56;
[13.14;
[ 1.71;
[ 1.81;
[ 7.67;
[ 1.25;
[ 1.07;
[ 0.62;
[ 0.81;
[ 0.79;
[ 0.66;
[ 0.91;
[ 0.63;
[ 0.31;
[ 0.54;
[ 0.75;

ChrY
Lung Cancer
Benign Cancer
Prostate Cancer
Any Cancer
Malignant Cancer
CLL
Epithelial Cancer
Myeloid Leukemia
MPN
Lymphoid Leukemia
Carcinoma in situ Cancer
Skin Cancer
Nervous System Cancer
Colorectal Cancer
Hematologic Cancer
ConnectiveTissue Cancer
Bladder Cancer

2.04
3.53
1.19
1.07
1.08
2.05
1.06
1.75
1.44
1.74
0.80
0.93
1.33
1.13
1.11
0.92
1.04

[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[

1.72;
1.78;
1.06;
1.02;
1.01;
1.04;
1.00;
0.96;
0.95;
0.90;
0.57;
0.82;
0.85;
0.91;
0.91;
0.63;
0.82;

ChrX
Hematologic Cancer
CLL
Lymphoid Leukemia
Malignant Cancer
Epithelial Cancer
Any Cancer
Colorectal Cancer
Skin Cancer
Breast Cancer
Lung Cancer
Carcinoma in situ Cancer

5.14
24.10
18.47
1.58
1.52
1.40
2.11
1.33
0.78
1.16
1.07

[
[
[
[
[
[
[
[
[
[
[

2.66; 9.9]
5.82; 99.9]
4.50; 75.7]
1.14; 2.2]
1.08; 2.1]
1.05; 1.9]
0.68; 6.5]
0.67; 2.7]
0.32; 1.9]
0.29; 4.7]
0.27; 4.3]

0.9

0.25 0.50 1.00

Cell fraction

5

10
HR

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N

4.6]
38.5]
49.6]
1.4]
1.4]
5.6]
2.2]
5.9]
1.2]
4.6]
1.3]
1.4]
1.2]
1.2]
1.7]
1.3]
1.4]
1.4]

2.6e‚àí132
9.5e‚àí119
4.3e‚àí115
8.8e‚àí38
1.1e‚àí28
9.6e‚àí28
6.1e‚àí16
1.8e‚àí10
2.6e‚àí07
0.0012
0.0037
0.062
0.11
0.36
0.57
0.59
0.61
0.96

3,744
405
342
56,778
38,346
650
2,619
255
36,419
280
4,787
2,463
9,396
5,378
732
1,573
2,499
959

440,455
443,794
443,857
387,421
405,853
443,366
441,145
443,944
407,780
443,919
435,576
439,230
422,188
428,551
443,467
441,315
441,700
443,240

523
163
155
2,586
2,037
101
229
34
1,652
14
428
138
456
38
29
111
71
50

11,875
12,235
12,243
9,812
10,361
12,274
12,147
12,364
10,746
12,384
11,606
12,153
11,425
12,268
12,369
12,179
12,327
12,348

18.9]
126.8]
158.9]
22.5]
2.0]
2.2]
19.7]
1.8]
2.3]
6.1]
1.9]
1.9]
2.5]
1.2]
1.3]
2.2]
1.7]
1.4]

0
3.8e‚àí299
4.2e‚àí277
3.3e‚àí95
3.3e‚àí51
7.6e‚àí51
2.3e‚àí25
2.3e‚àí05
0.02
0.26
0.32
0.35
0.46
0.63
0.66
0.71
0.87
0.88

3,744
405
342
650
56,778
38,346
255
9,396
2,619
280
2,463
2,499
959
36,419
5,378
732
1,573
4,787

440,455
443,794
443,857
443,366
387,421
405,853
443,944
422,188
441,145
443,919
439,230
441,700
443,240
407,780
428,551
443,467
441,315
435,576

399
158
150
76
693
569
21
112
33
3
26
20
10
297
32
4
13
43

2,586
2,827
2,835
2,889
2,292
2,416
2,964
2,762
2,949
2,982
2,937
2,965
2,975
2,688
2,879
2,981
2,958
2,887

5.7e‚àí16
0.00032
0.0027
0.0072
0.014
0.038
0.062
0.068
0.088
0.1
0.17
0.21
0.22
0.26
0.29
0.64
0.76

1,402
104
4,784
28,582
19,983
219
18,308
149
357
250
883
5,073
347
1,362
2,113
590
1,177

202,938
204,475
195,961
175,997
184,596
204,360
186,271
204,430
204,095
204,329
203,696
193,754
204,232
201,801
202,466
203,989
202,432

197
12
389
1,873
1,451
13
1,324
14
31
13
49
335
26
110
136
40
97

8,953
9,156
8,463
7,295
7,717
9,155
7,844
9,154
9,134
9,155
9,119
8,436
9,142
8,970
9,032
9,128
8,980

1e‚àí06
1.1e‚àí05
5.1e‚àí05
0.0061
0.015
0.023
0.2
0.42
0.58
0.83
0.92

1,631
123
155
18,363
18,111
28,196
1,101
4,323
5,328
1,217
1,616

237,989
239,497
239,465
221,257
221,509
211,424
237,429
228,434
224,083
238,207
238,004

14
3
4
53
49
65
4
12
6
3
3

383
394
393
344
348
332
391
369
375
393
394

2.4]
7.0]
1.3]
1.1]
1.1]
4.0]
1.1]
3.2]
2.2]
3.4]
1.1]
1.0]
2.1]
1.4]
1.4]
1.3]
1.3]

50 100

Extended Data Figure 3: Association of mCAs with incident cancer in the UK Biobank.
Association of a) all mCA and b) autosomal mCA cell fraction with incident hematologic cancer.
The dotted vertical line at cell fraction of 0.1 shows the cutoff point for expanded mCAs (defined
as mCAs with cell fraction >10%). c) Association of expanded mCA categories ( with cell
fraction>10%) with incident cancer in the UK Biobank. Analyses are adjusted for age, age2, sex,
smoking status, and principal components of ancestry. Individuals with a history of hematologic
cancer at enrollment were removed from analysis. CLL = chronic lymphocytic leukemia, MPN =
myeloproliforative neoplasm, mCA = mosaic chromosomal alterations

31

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

a.

Incident Sepsis Cases

100

Copy Change
Gain

mCA Size (MB)

Loss
CNN‚àíLOH

Cell Fraction

10

0.2
0.4
0.6

0.8

1

1

b.

2

3

4

5

6

7

8

9

10

11 12 13
Chromosome

14

15

16

17

18

19

20

21

22

Incident Pneumonia Cases

100

Copy Change
Gain

mCA Size (MB)

Loss
CNN‚àíLOH

10

Cell Fraction
0.2
0.4
0.6

1

0.8

1

1
2
3
4
5
6
7
8

2

3

4

5

6

7

8

9

10

11 12 13
Chromosome

14

15

16

17

18

19

20

21

22

Extended Data Figure 4: Visualization of the diverse range of expanded autosomal mCAs
detected across the genome among individuals with a. incident sepsis and b. incident pneumonia
in the UKB. Each point represents one mCA carried by a case, with the x-axis as the
chromosome, y-axis as the mCA size in mega-bases of DNA (MB), color as the copy change,
and size of the point as the cell fraction of that mCA. CNN-LOH=copy number neutral loss of
heterozygosity, MB = megabases of DNA, mCA = mosaic chromosomal alterations

32

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

a.

Effect of Autosomal mCAs
on Incident Disease Mortality

HR

95% CI

Any Infection
All
Male
Female

1.12
1.11
1.13

Nervous System Infection
All
Male
Respiratory System Infection
All
Male
Female

0.8 1

2
HR

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

[1.01; 1.2]
[0.97; 1.2]
[0.93; 1.4]

0.037
0.12
0.22

1,998
1,329
669

72,317
39,978
32,339

476
346
130

10,485
6,298
4,187

2.81
3.71

[1.14; 6.9]
[1.40; 9.9]

0.025
0.0085

21
17

72,317
39,978

8
8

10,485
6,298

1.15
1.16
1.12

[1.02; 1.3]
[1.00; 1.3]
[0.86; 1.4]

0.028
0.05
0.39

1,353
971
382

72,317
39,978
32,339

346
269
77

10,485
6,298
4,187

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

5

Effect of Autosomal mCAs
on Incident Disease Mortality

b.

P

HR

95% CI

Cardiac Infection
All
Female

1.11
2.46

[0.56; 2.2]
[1.03; 5.9]

0.77
0.043

50
25

72,317
32,339

11
8

10,485
4,187

Meningitis or Encephalitis
All
Male

2.81
3.71

[1.14; 6.9]
[1.40; 9.9]

0.025
0.0085

21
17

72,317
39,978

8
8

10,485
6,298

Pneumonia
All
Male
Female

1.16
1.17
1.11

[1.02; 1.3]
[1.01; 1.4]
[0.86; 1.4]

0.023
0.039
0.42

1,299
928
371

72,317
39,978
32,339

334
259
75

10,485
6,298
4,187

0.8 1

2
HR

5

Effect of Expanded Autosomal mCAs
on Incident Disease Mortality
HR

c.

Sepsis
All
Male

2.04
1.95

0.8 1

2
HR

95% CI

[1.0; 4.2]
[0.8; 4.8]

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

0.05
0.14

276
164

72,317
39,978

8
5

753
471

5

Extended Data Figure 5: Suggestive associations (P<0.05) of mCAs with incident infectionrelated mortality in Biobank Japan. Associations of autosomal mCAs with a) organ-system level
infections and b) specific infection categories. c) Association of expanded autosomal mCAs with
Sepsis. Full results are in Supplementary Table 6. Associations are presented among individuals
without any cancer history. mCA = mosaic chromosomal alterations.

33

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Effect of Expanded Autosomal mCA
on Incident Disease
HR

1
Any Infection
+Prior Cancer History
‚àíPrior Cancer History

1.32
1.16

95% CI

[1.17; 1.49]
[1.03; 1.30]

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

6.2e‚àí06
0.013

20,885
43,366

61,104
207,415

306
294

579
1,199

2

Heterogeneity: p = 0.119

Sepsis
+Prior Cancer History
‚àíPrior Cancer History

2.79
1.25

[2.30; 3.38]
[0.80; 1.95]

9.7e‚àí26
0.33

4,058
2,405

137,278
380,507

119
21

1,434
2,197

1.60
1.16

[1.40; 1.82]
[1.00; 1.34]

6.1e‚àí12
0.045

14,381
29,434

97,737
285,895

251
190

972
1,653

1.48
1.46

[1.22; 1.79]
[1.20; 1.76]

6.2e‚àí05
0.00013

7,973
13,892

125,702
351,260

127
109

1,340
2,041

1.34
1.08

[1.14; 1.58]
[0.90; 1.31]

0.0004
0.4

11,299
17,153

111,100
334,731

175
114

1,184
1,929

2.72
3.14

[1.55; 4.78]
[1.48; 6.64]

0.00048
0.0028

412
10,143

134,381
291,483

13
59

1,425
1,596

1.24
1.04

[1.04; 1.49]
[0.89; 1.23]

0.019
0.6

9,754
24,573

110,192
314,845

138
154

1,158
1,877

1.07
1.66

[0.51; 2.27]
[0.95; 2.90]

0.85
0.075

557
1,506

133,880
382,324

11
14

1,420
2,226

1.15
1.98

[0.43; 3.09]
[0.88; 4.47]

0.79
0.1

333
949

133,745
382,520

4
9

1,426
2,231

1.45
1.03

[1.08; 1.96]
[0.79; 1.34]

0.014
0.81

3,467
10,953

129,493
352,331

50
65

1,433
2,078

Heterogeneity: p = 0.001

Respiratory System Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.001

Digestive System Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.906

Genitourinary System Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.091

Cardiac Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.768

Dermatologic Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.160

3

Musculoskeletal System Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.361

4

Nervous System Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.404

5

Eye, Ear, or Mastoid Infection
+Prior Cancer History
‚àíPrior Cancer History
Heterogeneity: p = 0.092

7
8
9
10
11
12
13
14
15
16

0.8 1

2

64

HR

Extended Data Figure 6: Association of expanded autosomal mCAs with incident infections
across individuals with and without a cancer history before their incident infection, metaanalyzed across UKB, MGBB, and FinnGen combined (cohort-specific analyses are available in
Supplementary Figure 15). Individuals with known hematologic cancer at time of or prior to
blood draw for genotyping were excluded. Analyses are adjusted for age, age2, sex, smoking
status, and principal components of ancestry. mCA = Mosaic chromosomal alteration, MGBB =
Mass General Brigham Biobank, UKB = UK Biobank

34

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
International license .
UK BiobankIt is made available under a CC-BY-NC-ND
MGB4.0Biobank

a.
0.100

0.050

0.025

0.000

+++++++++++++++++++++++++++++++++++++++++++
+
+
++
+
+
++++++
+
++
+
+
+
+
+
+
+++++++++
++
+
+++++
+
++++
+
+++
+++
+++
+++
+
+
+
+
++
+++
++++++++++
+++++++++++
+++++
+++++++++++++++
++++++++++
+
+++++++++++
+
+
+
+
+
+++
+
+
+
+
++++
++++++++++
++++++++++
++
++++++++++++++
++++
+++++++++++++
++++++++++++++
+
+++
+
+
+
+
+++++++++++++++++++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
++
+
+
+++++
+
+
++++
+
+
+
+++++++++++
+
+
++
++
++
++
++
++
++
++
++
++
++
++
+
+
+++++++++++++
+
+
+
+
+
++ ++++++++++++++++++++++++++++++++++++++++++ +++ + +++++++++++++++
+++++++++++++++++++++++++++++++
+
++
+
++
++
+++
++
++
++
++
++
++
++
+
+
+
+
+
++
+
++++++++++++++++
++
++
+
++
+
+
+
+
+
++
++
++
+
++
+
+++++++
++
+
+
+
+
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ +++++++++++++++++++++
+++
+++++++++++++++
++
+
+
+
++
++
++
++
+
++
+
++
++++++++++++++++
0

3

6

+++++++++

0.100

Cumulative Proportion

Cumulative Proportion

0.075

0.075

0.050

0.025

0.000

++

9

++++++++++++++++++++++
++++++++++++
++++++
++
++
+
+
+++++
+ +++
+++++++++++++++++++++++++++++++++++++++++
+++++++++++++++++
+++++++++++
++
+++++++++++++
+ +++++++++++++++++++
++++
++
++++++++++++
++++++++++++
+
+++++++
+
+
+
+
+
+
+
+
+ +++
+
+
+
+
+
+
+
+++++++++++++++++
++++++
++
+++++++++++++++++++ +++++++++++++++++++++++++++++++++++++++++++++++++
+++++++++++++++++++
++++++++++
++++++
++
++++++
++++
+++
+++
+++++++++++++++++++++++++++++++++++++++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+++++++++++++++
++
++++++++++++++++++++
+++++++++++++++++
+++++
++
0

Years
Number at risk

1175
99039
1742
274719
3

1084
95230
1718
272561
6

195
17062
320
49854
9

Strata

Strata

1230
101194
1751
276023
0

+mCA +Cancer
‚àímCA +Cancer
+mCA ‚àíCancer
‚àímCA ‚àíCancer

204
9348
128
9221
0

Years

Cumulative Proportion

0.15

0.10

0.05

0.00

++
++
+++
++
+
+++++++++++++
++
++++
++
+
+++
++
++
+
+
+
+
+
+
+
+
+
++++
++++++
+
+++++
+++
++
++
++++
+++
+++
+++
+
+
+
+++
++
++++++
+
+++++++
+++++++++
++
+++++++++
+
+
+
+
+
+
+
+++++
+
++++++++++++++++
++++++++
++
+++
++++++++++
++++++ ++
++++
++++++++++
+++++++++++++
++++
++
++
+++++++++++
+
+
+
+
+
+
+
+
+++
+
+
++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+++++
+++
++++++++++++++++
++++++++
+
+
+
+
+
+
++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
++++
++
+++
++++++++++++++++++
+++++++
++
++++
++++
+
+
+ ++++++++++++
+
++++++++++++++++++++++++++++++
+++++++++++++
++
++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++++++++++++++++++++
++ +++
+
+
+
+
+
+
+
+
+
+
++
++
+
++
+++++++++++++++++++++++++++++++++++++++++++
+
+
+
+
++
+
+
+
+
+
+
+
+
+++
++
++++++++++++
++
+++
+++
++
+++++++++++++++++
0

3

6

0.20
++++++++++

0.15

+++++ +++++

0.10

0.05

0.00

++

9

++++++++
++++++++++++++++
+++++++++++++++++
++
+++
++
+++
++
+
+++
++
++
+++++++++
++++
+++++
++
+
+
++
+
+
+
+
+
+++++++
++++++++++++++++++
+++++++
++
+++++++++
+
+
+ +++++++
+++++
+
+
+
+
++++
+
+
+++++
+++++++
+++++++
+++++++++ ++++++++++++++++++++++++++++++++++
+++++++++++
++
+
+++++++++ +++++++++++++++++++++++
+
++++++++++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
++++++++++++++++++++++
++
++
++
++
++
++
++
+
+
+
+
+ + ++
+
+
++
+
+
+
+
++
++
++
++
+
++++++
+
++++++++++++++++++
++++++++++++
+++
++
+++++
++
++++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
++
+
+
++
+++++++++++++
++
+++++
+
++
+++
++
+++++
+
0

Years
Number at risk

1123
96382
1698
268831
3

1034
92490
1671
265703
6

177
16454
304
48178
9

Strata

Strata

1178
98608
1715
270985
0

+mCA +Cancer
‚àímCA +Cancer
+mCA ‚àíCancer
‚àímCA ‚àíCancer

198
9088
127
9172
0

Years

c.

2.5
Years

Number at risk

+mCA +Cancer
‚àímCA +Cancer
+mCA ‚àíCancer
‚àímCA ‚àíCancer

124
6664
83
6953
2.5
Years

Cumulative Proportion

b.

2.5
Years

Number at risk

+mCA +Cancer
‚àímCA +Cancer
+mCA ‚àíCancer
‚àímCA ‚àíCancer

122
6308
79
6742
2.5
Years

0.15

0.15

++++++++++
+++++++++++

++++++++++

++++

0.05

0.00

+++++++++++++++++++++
+++++++++
++
++++
+
+++++++++
+
+
+++++
+++++++
++++++++
+++++++++
++++++
+++++++++
+++
++++++++
++
++
+
+
+
++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+++
+
+
+
+
+
+
+++
++++++++++++++++
+++
++++
++
++
++
++
++++++++++
++
+
++++++++++++++++++++++
+++++++++
+
+
+
++
++ ++++++++++++++++
+
+
+
+
+
+
+
+
+
+
++++++++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+++ +++ ++++++
+++++++++++
++++ + +++++++++++ ++++++++++++++++++++
+++ ++++++++++++++++++++++++++++++++++++++++++
+++++++++++++++++
++++
++++++++++
+++++++
+++++
+
+
+
+
+
+
+
++
+++
++++++++ ++++++++++
++
++
++++++++
+++++++++++++++++
++++++++++
+
+++++++++++++++++++++
++++++++++++++++++
++++++++++++++++++++++++++
0

3

6

9

990
87798
1598
255507
6

171
15551
303
46212
9

Cumulative Proportion

Cumulative Proportion

++++

0.10

0.10

+++++++++++++
++++++++++++++++++++++++++++++ +++++++++++++++
+
+++++++
+++++++++
+++++++
++++++++
++++
++++++++
++
++
++
++
+
++++++++
+
+++++
+++++++++
+++++++++++
+
+
++
+
+
+
+
+
+
+
+
+
+ + ++
++++++
+++++++
+
++++++++++
+
+
+
++++++++++
+++++++++++
++
++++++++++
+++
++++++++
++++++++++++
+++++++++
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ + +++++++++++++ ++++++++++
+
++++++++++ ++++++++
++++
+++++++ ++++++++++
+
++++++ +++++++++++++
+
++++++++++++++++++++++++++
+
++++++++++++++++
++++++++++++
++
+++ ++++++++
++++++++
+++
+++++++++
+
+
+++
+++
++

0.05

0.00

++

0
Number at risk

1097
92938
1661
261721
3
Years

1
2
3
4
5
6
7
8
9

Strata

Strata

Number at risk

1155
95532
1701
265429
0

2.5
Years

Years

+mCA +Cancer
‚àímCA +Cancer
+mCA ‚àíCancer
‚àímCA ‚àíCancer

FinnGen

0.125

+mCA +Cancer
‚àímCA +Cancer
+mCA ‚àíCancer
‚àímCA ‚àíCancer

195
8943
128
9142
0

119
6194
75
6597
2.5
Years

Extended Data Figure 7: Association of expanded autosomal mCAs with incident a. sepsis, b.
pneumonia, and c. digestive system infection across carrier status for expanded autosomal mCAs
and any cancer diagnosis prior to the incident infection date. Individuals with known
hematologic cancer at time of or prior to blood draw for genotyping were excluded. mCA =
mosaic chromosomal alterations.

35

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

a.

Effect of Expanded mCAs
on Severe COVID‚àí19

OR

95% CI

Unadjusted
All
Male
Female

2.05
1.75
1.48

Sparsely Adjusted
All
Male
Female
Fully Adjusted
All
Male
Female

0.8 1

2
OR

4

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

[1.51; 2.8]
[1.26; 2.4]
[0.55; 4.0]

4.4e‚àí06
0.0008
0.44

719
392
327

337,877
144,956
192,921

44
40
4

10,435
8,832
1,603

1.59
1.41
1.97

[1.13; 2.2]
[0.97; 2.0]
[0.73; 5.3]

0.0082
0.069
0.18

719
392
327

337,877
144,956
192,921

44
40
4

10,435
8,832
1,603

1.65
1.48
2.09

[1.17; 2.3]
[1.01; 2.1]
[0.77; 5.6]

0.0045
0.042
0.15

518
281
237

273,694
117,396
156,298

39
35
4

8,825
7,547
1,278

6

Effect of Expanded mCAs
on COVID‚àí19 phenotypes

b.

OR

95% CI

COVID‚àí19 Hospitalization vs. All
All
Autosomal
ChrY
ChrX

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

1.65
2.23
1.36
3.02

[1.17; 2.3]
[1.18; 4.2]
[0.91; 2.0]
[0.42; 21.7]

0.0045
0.013
0.14
0.27

518
489
275
234

273,694
266,987
116,443
155,242

39
10
29
1

8,825
2,118
6,594
222

COVID‚àí19 Positive vs. All
All
Autosomal
ChrY
ChrX

1.47
1.57
1.28
3.38

[1.09; 2.0]
[0.86; 2.9]
[0.90; 1.8]
[0.83; 13.7]

0.012
0.14
0.18
0.088

877
838
435
432

273,671
266,964
116,432
155,230

50
11
38
2

8,825
2,118
6,594
222

COVID‚àí19 Hospitalization vs. COVID‚àí19 Negative
All
Autosomal
ChrY
ChrX

1.58
1.85
1.43
1.78

[1.09; 2.3]
[0.94; 3.7]
[0.93; 2.2]
[0.22; 14.7]

0.015
0.075
0.11
0.59

518
489
275
234

6,329
6,114
2,815
3,450

39
10
29
1

283
68
211
8

COVID‚àí19 Positive vs. COVID‚àí19 Negative
All
Autosomal
ChrY
ChrX

1.37
1.32
1.32
2.04

[0.99;
[0.69;
[0.90;
[0.42;

0.057
0.41
0.16
0.37

877
838
435
432

6,329
6,114
2,815
3,450

50
11
38
2

283
68
211
8

0.8 1

Effect of Expanded mCAs
on Incident Pneumonia

c.

2
OR

HR

95% CI

All
All
Male
Female

1.33
1.31
1.46

Autosomal
All
Male
Female
ChrY
Male
ChrX
Female

0.8

1

2

4

1.9]
2.5]
1.9]
9.9]

6

P

Cases (N)

Controls (N)

Cases with mCA (N)

Controls with mCA (N)

[1.2; 1.4]
[1.2; 1.4]
[1.1; 1.9]

7.4e‚àí11
6.6e‚àí09
0.0064

11,251
6,458
4,793

422,497
192,740
229,757

720
648
72

11,273
9,526
1,747

1.87
2.14
1.40

[1.6; 2.2]
[1.8; 2.6]
[1.0; 1.9]

1.1e‚àí13
2.3e‚àí14
0.033

11,251
6,458
4,793

422,497
192,740
229,757

175
121
54

2,718
1,326
1,392

1.22

[1.1; 1.4]

0.00011

6,458

192,740

543

8,316

1.84

[1.0; 3.2]

0.035

4,793

229,757

20

369

3

HR

1
2
3
4
5
6
7
8
9
10
11

Extended Data Figure 8: Associations of expanded mCAs in the UK Biobank with COVID-19
and incident pneumonia. Associations of expanded mCAs with a. COVID-19 hospitalization
across different adjustment models, and b. different COVID-19 phenotypes in a fully adjusted
model. Adjustment models include 1) an unadjusted model, 2) a sparsely adjusted model which
adjusts for age, age2, sex, smoking status, and principal components of ancestry, and 3) a fully
adjusted model which additionally adjusts for Townsend deprivation index, BMI, and the
following comorbidities: Asthma, COPD, CAD, T2D, any cancer, and HTN. mCA = mosaic
chromosomal alterations, COPD = chronic obstructive pulmonary disease, CAD = coronary
artery disease, T2D = type 2 diabetes mellitus. c. Association of expanded mCAs with incident
pneumonia stratified by sex, adjusted for age, age2, sex (in the All model only), smoking status,
and principal components of ancestry. mCA = mosaic chromosomal alterations

36

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

b
.

a.
Immunoglobulin Class‚àíSwitch
Recombination via Classical non‚àí
Homologous End‚àíJoining
AMPK Related Catabolism Deceleration in
Glucose Insufficiency

MDC1;ATM
SREBF1;ATG13
TAL1;ATM;IKZF1

Proteins Involved in T‚àíCell Acute
Lymphoblastic Leukemia

FLT3;TCF12;IKZF1

Hematopoietic Cell Lineage: B‚àícell
(mouse)

TAL1;TCF12

T‚àíCell Genetic Rearrangements in Acute
Lymphoblastic Leukemia

SIN3A;IKZF1

NURD in Chromatin Remodeling

MDC1;ATM

Double Strand DNA Homologous Repair

LPAR2;PIK3CB;F2

EGFR Transactivation in Cancer and Non‚àí
Cancer Cells

CD164;FLT3;NCAM1

Myeloblast ‚àí> Neutrophil Surface
Expression Markers
Proteins Involved in Myocarditis
IL23A and IL17A Provoke Cancer‚àí
Associated Inflammation

NCAM1;PDCD1LG2;F2;
IL12RB1;NFKB1
IL12RB1;NFKB1
DOK1;CD200

Microglia and Motor Neuron Interaction
Dysregulation
mTOR Signaling

SREBF1;DAP;ATG13
MDC1;ATM

Persistent Double Strand DNA Homologous
Repair in Cancer

MDC1;ATM

Persisted DNA Repair Triggers Genomic
Instability

ATG13;NFKB1

SCF/BTRC Complex
Proteins Involved in Spontaneous
Abortion

NCAM1;F2;CD200
FLT3;IKZF1

Hematopoietic Cell Lineage: B‚àícell
0

1
2
3
4
5
6
7
8

1
2
Enrichment - log10 (P)

3

Extended Data Figure 9: Pathway enrichment of TWAS results using the Elsevier Pathways. a.
Top results from pathway enrichment analysis of the TWAS results using the Elsevier Pathways.
b. Highlighting the GWAS locus-zoom plots for some of the TWAS genes implicated in the top
pathways from panel b. Red boxes highlight the gene(s) with strongest association in the TWAS
analyses. GWAS = genome-wide association study, TWAS = transcriptome-wide association
study

37

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2

Sepsis

Pneumonia

3
4
5
6
7
8
9
10
11
12
13
14

Adjustment

HR

P

Lower
95% CI

Upper
95% CI

Chemotherapy

2.48

3.04E-17

2.01

3.06

Neutropenia

1.65

3.98E-06

1.33

2.04

Aplastic anemia

2.58

1.84E-18

2.09

3.19

Decreased white blood cell count

1.65

3.98E-06

1.33

2.04

Bone marrow or stem cell transplant

2.77

3.25E-21

2.24

3.42

Effects radiation NOS

2.84

2.85E-22

2.30

3.51

Chemotherapy

2.11

1.47E-14

1.74

2.55

Neutropenia

1.99

1.38E-12

1.65

2.41

Aplastic anemia

2.16

2.17E-15

1.79

2.62

Decreased white blood cell count

1.99

1.38E-12

1.65

2.41

Bone marrow or stem cell transplant

2.20

5.04E-16

1.82

2.66

Effects radiation NOS

2.27

2.59E-17

1.88

2.75

Extended Table 1: Sensitivity analysis of expanded autosomal mCA with incident sepsis and
with pneumonia association in the UK Biobank among those with cancer prior to incident
infection, separately adjusting for chemotherapy, neutropenia, aplastic anemia, decreased white
blood cell count, bone marrow or stem cell transplant, and radiation effects prior to infection (as
defined using the Vanderbilt ICD-10 and ICD-9 phecode groupings10). Other covariates in the
model included age, age2, sex, smoking status, and PC1-10 of ancestry. The summary stats (HR,
P-value, 95% CI) reflect those for the expanded autosomal mCA term in each model.
CI = confidence interval; HR = hazard ratio; mCA = mosaic chromosomal alteration; N =
number; NOS = not otherwise specified

38

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

References
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Gardner, I. D. The effect of aging on susceptibility to infection. Rev Infect Dis 2, 801810, doi:10.1093/clinids/2.5.801 (1980).
Gavazzi, G. & Krause, K. H. Ageing and infection. Lancet Infect Dis 2, 659-666,
doi:10.1016/s1473-3099(02)00437-1 (2002).
Terao, C. et al. Chromosomal alterations among age-related haematopoietic clones in
Japan. Nature, doi:10.1038/s41586-020-2426-2 (2020).
Loh, P. R., Genovese, G. & McCarroll, S. A. Monogenic and polygenic inheritance
become instruments for clonal selection. Nature, doi:10.1038/s41586-020-2430-6 (2020).
Loh, P. R. et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal
alterations. Nature 559, 350-355, doi:10.1038/s41586-018-0321-x (2018).
Lin, S. H. et al. Mosaic chromosome Y loss is associated with alterations in blood cell
counts in UK Biobank men. Sci Rep 10, 3655, doi:10.1038/s41598-020-59963-8 (2020).
Forsberg, L. A. et al. Mosaic loss of chromosome Y in peripheral blood is associated
with shorter survival and higher risk of cancer. Nat Genet 46, 624-628,
doi:10.1038/ng.2966 (2014).
Jacobs, K. B. et al. Detectable clonal mosaicism and its relationship to aging and cancer.
Nat Genet 44, 651-658, doi:10.1038/ng.2270 (2012).
Laurie, C. C. et al. Detectable clonal mosaicism from birth to old age and its relationship
to cancer. Nat Genet 44, 642-650, doi:10.1038/ng.2271 (2012).
Loftfield, E. et al. Predictors of mosaic chromosome Y loss and associations with
mortality in the UK Biobank. Sci Rep 8, 12316, doi:10.1038/s41598-018-30759-1 (2018).
Machiela, M. J. et al. Characterization of large structural genetic mosaicism in human
autosomes. Am J Hum Genet 96, 487-497, doi:10.1016/j.ajhg.2015.01.011 (2015).
Aw, D., Silva, A. B. & Palmer, D. B. Immunosenescence: emerging challenges for an
ageing population. Immunology 120, 435-446, doi:10.1111/j.1365-2567.2007.02555.x
(2007).
Franceschi, C., Bonafe, M. & Valensin, S. Human immunosenescence: the prevailing of
innate immunity, the failing of clonotypic immunity, and the filling of immunological
space. Vaccine 18, 1717-1720, doi:10.1016/s0264-410x(99)00513-7 (2000).
Ongradi, J. & Kovesdi, V. Factors that may impact on immunosenescence: an appraisal.
Immun Ageing 7, 7, doi:10.1186/1742-4933-7-7 (2010).
Panda, A. et al. Human innate immunosenescence: causes and consequences for
immunity in old age. Trends Immunol 30, 325-333, doi:10.1016/j.it.2009.05.004 (2009).
Aoshi, T., Koyama, S., Kobiyama, K., Akira, S. & Ishii, K. J. Innate and adaptive
immune responses to viral infection and vaccination. Curr Opin Virol 1, 226-232,
doi:10.1016/j.coviro.2011.07.002 (2011).
Holly, M. K., Diaz, K. & Smith, J. G. Defensins in Viral Infection and Pathogenesis.
Annu Rev Virol 4, 369-391, doi:10.1146/annurev-virology-101416-041734 (2017).
Pallett, L. J., Schmidt, N. & Schurich, A. T cell metabolism in chronic viral infection.
Clin Exp Immunol 197, 143-152, doi:10.1111/cei.13308 (2019).
Wu, P. et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow
Development and Initial Evaluation. JMIR Med Inform 7, e14325, doi:10.2196/14325
(2019).

39

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Thompson, D. J. et al. Genetic predisposition to mosaic Y chromosome loss in blood.
Nature 575, 652-657, doi:10.1038/s41586-019-1765-3 (2019).
Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. Science 369, 1318-1330, doi:10.1126/science.aaz1776 (2020).
Lu, Q. et al. Systematic tissue-specific functional annotation of the human genome
highlights immune-related DNA elements for late-onset Alzheimer's disease. PLoS Genet
13, e1006933, doi:10.1371/journal.pgen.1006933 (2017).
Bick, A. G. et al. Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular
Risk in Clonal Hematopoiesis. Circulation 141, 124-131,
doi:10.1161/CIRCULATIONAHA.119.044362 (2020).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood
DNA sequence. N Engl J Med 371, 2477-2487, doi:10.1056/NEJMoa1409405 (2014).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N
Engl J Med 371, 2488-2498, doi:10.1056/NEJMoa1408617 (2014).
Jaiswal, S. et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular
Disease. N Engl J Med 377, 111-121, doi:10.1056/NEJMoa1701719 (2017).
Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and
malignancies. Nat Med 20, 1472-1478, doi:10.1038/nm.3733 (2014).
Wang, L. et al. Integrated single-cell genetic and transcriptional analysis suggests novel
drivers of chronic lymphocytic leukemia. Genome Res 27, 1300-1311,
doi:10.1101/gr.217331.116 (2017).
de Weerdt, I. et al. Innate lymphoid cells are expanded and functionally altered in chronic
lymphocytic leukemia. Haematologica 101, e461-e464,
doi:10.3324/haematol.2016.144725 (2016).
Bartik, M. M., Welker, D. & Kay, N. E. Impairments in immune cell function in B cell
chronic lymphocytic leukemia. Semin Oncol 25, 27-33 (1998).
Arruga, F. et al. Immune Response Dysfunction in Chronic Lymphocytic Leukemia:
Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int J Mol Sci 21,
doi:10.3390/ijms21051825 (2020).
Zhou, W. et al. Mosaic loss of chromosome Y is associated with common variation near
TCL1A. Nat Genet 48, 563-568, doi:10.1038/ng.3545 (2016).
Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological Effects of
Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 28, 690-714,
doi:10.1016/j.ccell.2015.10.012 (2015).
Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357,
539-545, doi:10.1016/S0140-6736(00)04046-0 (2001).
de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system
during cancer development. Nat Rev Cancer 6, 24-37, doi:10.1038/nrc1782 (2006).
Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID19. Nature, doi:10.1038/s41586-020-2588-y (2020).
Giamarellos-Bourboulis, E. J. et al. Complex Immune Dysregulation in COVID-19
Patients with Severe Respiratory Failure. Cell Host Microbe 27, 992-1000 e1003,
doi:10.1016/j.chom.2020.04.009 (2020).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet 395, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).

40

medRxiv preprint doi: https://doi.org/10.1101/2020.11.12.20230821; this version posted November 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

39
40
41
42
43
44
45
46
47

Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. & Riella, L. V. Remodeling of the
Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID19 Immune Response. Front Immunol 11, 1748, doi:10.3389/fimmu.2020.01748 (2020).
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data.
Nature 562, 203-209, doi:10.1038/s41586-018-0579-z (2018).
Nagai, A. et al. Overview of the BioBank Japan Project: Study design and profile. J
Epidemiol 27, S2-S8, doi:10.1016/j.je.2016.12.005 (2017).
Smoller, J. W. et al. An eMERGE Clinical Center at Partners Personalized Medicine. J
Pers Med 6, doi:10.3390/jpm6010005 (2016).
Peiffer, D. A. et al. High-resolution genomic profiling of chromosomal aberrations using
Infinium whole-genome genotyping. Genome Res 16, 1136-1148,
doi:10.1101/gr.5402306 (2006).
Townsend, P., Phillimore P., Beattie A. Health and deprivation. Inequality and the North.
Health Policy 10 (1989).
Finucane, H. K. et al. Partitioning heritability by functional annotation using genomewide association summary statistics. Nat Genet 47, 1228-1235, doi:10.1038/ng.3404
(2015).
Hu, Y. et al. A statistical framework for cross-tissue transcriptome-wide association
analysis. Nat Genet 51, 568-576, doi:10.1038/s41588-019-0345-7 (2019).
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server
2016 update. Nucleic Acids Res 44, W90-97, doi:10.1093/nar/gkw377 (2016).

41

